US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US20050241006A1
(en)
*
|
1995-04-27 |
2005-10-27 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US20050287630A1
(en)
*
|
1995-04-27 |
2005-12-29 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US7129061B1
(en)
*
|
1996-08-07 |
2006-10-31 |
Biogen Idec Ma Inc. |
Tumor necrosis factor related ligand
|
CA2722378C
(en)
*
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
US6541212B2
(en)
*
|
1997-03-10 |
2003-04-01 |
The Regents Of The University Of California |
Methods for detecting prostate stem cell antigen protein
|
AU777918B2
(en)
*
|
1997-05-05 |
2004-11-04 |
Amgen Fremont Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
DK1032674T3
(da)
|
1997-11-21 |
2007-04-10 |
Serono Genetics Inst Sa |
Chlamydia pneumoniae genomisk sekvens og polypeptider, fragmenter deraf og anvendelser deraf, især til diagnosen, forebyggelsen og behandlingen af infektion
|
EP1032676A2
(en)
|
1997-11-28 |
2000-09-06 |
Genset |
$i(CHLAMYDIA TRACHOMATIS) GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION
|
AU757698C
(en)
|
1998-06-01 |
2004-04-08 |
Agensys, Inc. |
Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
|
GB9823930D0
(en)
*
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
NZ512553A
(en)
|
1998-12-23 |
2004-02-27 |
Pfizer |
Human monoclonal antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4)
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
BR0008772B1
(pt)
|
1999-03-09 |
2011-11-01 |
|
vetor de expressão, célula bacteriana ou fúngica cultivada, processos para expandir in vitro células hematopoiéticas e progenitores de células hematopoiéticas, e para detectar a presença de rna de ligando zalfa11 e de ligando zalfa 11 in vitro em uma amostra biológica.
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US7883704B2
(en)
*
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
IL145775A0
(en)
|
1999-04-12 |
2002-07-25 |
Agensys Inc |
13 transmembrane protein expressed in prostate cancer
|
EP1792989A1
(en)
|
1999-04-12 |
2007-06-06 |
Agensys, Inc. |
13 Transmembrane protein expressed in prostate cancer
|
DK2314315T3
(en)
|
1999-06-01 |
2015-02-02 |
Biogen Idec Inc |
Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
|
US6833268B1
(en)
*
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
ATE420175T1
(de)
|
1999-08-12 |
2009-01-15 |
Agensys Inc |
C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
|
KR100942863B1
(ko)
|
1999-08-24 |
2010-02-17 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
AU7491800A
(en)
*
|
1999-09-15 |
2001-04-17 |
Therapeutic Human Polyclonals, Inc. |
Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
|
IL147952A0
(en)
|
1999-10-05 |
2002-08-14 |
Agensys Inc |
G protein-coupled receptor up-regulated in prostate cancer and uses thereof
|
US6893818B1
(en)
|
1999-10-28 |
2005-05-17 |
Agensys, Inc. |
Gene upregulated in cancers of the prostate
|
ATE459716T1
(de)
|
1999-12-23 |
2010-03-15 |
Zymogenetics Inc |
Zytokin zcyt018
|
EP2338515A3
(en)
|
2000-02-10 |
2011-11-16 |
Abbott Laboratories |
Antibodies that bind human interleukin-18 and methods of making and using
|
WO2001077361A1
(en)
*
|
2000-04-10 |
2001-10-18 |
American Biogenetic Sciences, Inc. |
Human immunoglobulin-producing gnotobiotics
|
CA2405912A1
(en)
|
2000-04-12 |
2001-10-18 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
WO2002002641A1
(en)
|
2000-06-16 |
2002-01-10 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to blys
|
WO2002000721A2
(en)
|
2000-06-26 |
2002-01-03 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17
|
HUP0301002A3
(en)
|
2000-06-29 |
2005-12-28 |
Abbott Lab |
Dual specificity antibodies and methods of making and using
|
DE60128093T2
(de)
|
2000-06-30 |
2007-12-27 |
Zymogenetics, Inc., Seattle |
Interferon-ähnliches protein zcyto21
|
ES2323407T3
(es)
|
2000-07-12 |
2009-07-15 |
Agensys, Inc. |
Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon.
|
EP2044839A3
(en)
*
|
2000-08-03 |
2009-07-01 |
Therapeutic Human Polyclonals, Inc. |
Production of humanized antibodies in transgenic animals
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
CA2420990C
(en)
|
2000-08-28 |
2010-08-17 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
|
EP1326626B1
(en)
|
2000-10-18 |
2020-04-01 |
Immunex Corporation |
Methods for treating rheumatoid arthritis using il-17 antagonists
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
CN1486365B
(zh)
|
2000-11-17 |
2010-05-12 |
协和发酵麒麟株式会社 |
异种(人类)免疫球蛋白在克隆转基因有蹄类动物中的表达
|
JP4434580B2
(ja)
|
2000-11-28 |
2010-03-17 |
メディミューン,エルエルシー |
予防及び治療のために抗rsv抗体を投与/処方する方法
|
WO2002046477A2
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
EP2354149B1
(en)
|
2000-12-12 |
2017-08-30 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
AU2002246733B2
(en)
*
|
2000-12-19 |
2007-09-20 |
Altor Bioscience Corporation |
Transgenic animals comprising a humanized immune system
|
CA2433800C
(en)
|
2001-01-05 |
2016-09-13 |
Pfizer Inc. |
Antibodies to insulin-like growth factor i receptor
|
WO2002064612A2
(en)
|
2001-02-09 |
2002-08-22 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2440676A1
(en)
|
2001-03-22 |
2002-10-03 |
Abbott Gmbh & Co. Kg |
Transgenic animals expressing antibodies specific for genes of interest and uses thereof
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002083921A2
(en)
|
2001-04-10 |
2002-10-24 |
Agensys, Inc. |
Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
UA83791C2
(ru)
|
2001-04-13 |
2008-08-26 |
Байоджен Айдек Ма Инк. |
Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
|
JP2005519580A
(ja)
|
2001-05-16 |
2005-07-07 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ |
非ヒト動物由来のヒト抗肺炎球菌抗体
|
MXPA03010747A
(es)
|
2001-05-25 |
2004-03-02 |
Human Genome Sciences Inc |
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
|
ES2674888T3
(es)
|
2001-06-26 |
2018-07-04 |
Amgen Inc. |
Anticuerpos para OPGL
|
ES2537074T3
(es)
|
2001-09-06 |
2015-06-02 |
Agensys, Inc. |
Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
ES2645698T3
(es)
|
2001-11-30 |
2017-12-07 |
Amgen Fremont Inc. |
Animales transgénicos que portan genes de cadena ligera de Ig humana
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
EP1467756A4
(en)
|
2001-12-28 |
2007-03-21 |
Abgenix Inc |
METHODS OF USING ANTI-MUC18 ANTIBODIES
|
CA2472154A1
(en)
|
2001-12-28 |
2003-07-17 |
Abgenix, Inc. |
Use of antibodies against the muc18 antigen
|
US7135174B2
(en)
*
|
2002-01-07 |
2006-11-14 |
Amgen Fremont, Inc. |
Antibodies directed to PDGFD and uses thereof
|
KR100668538B1
(ko)
*
|
2002-01-09 |
2007-01-16 |
메다렉스, 인코포레이티드 |
Cd30에 대한 인간 모노클로날 항체
|
BR0306979A
(pt)
|
2002-01-18 |
2004-11-23 |
Zymogenetics Inc |
Polipeptìdeo isolado, proteìna de fusão, molécula isolada de polinucleotìdeo, vetor de expressão, célula cultivada, anticorpo ou fragmento de anticorpo, e, métodos para produzir uma proteìna, para produzir um anticorpo, para estimular uma resposta imune em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para detectar a presença de rna zcytor17lig e de zcytor17lig em uma amostra biológica, para matar cérlulas cancerìgenas, para inibir a proliferação induzida por zcytor17lig ou diferenciação de células hematopoiéticas e progenitoras de células hematopoiéticas, para reduzir a inflamação induzida por zcytor17lig para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero acometido por uma doença inflamatória e para detectar inflamação em um paciente
|
AU2003280410B8
(en)
|
2002-01-18 |
2009-04-23 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
CN102659945B
(zh)
|
2002-01-25 |
2016-12-21 |
诺沃挪第克公司 |
抗C5aR抗体及其应用
|
CA2479730A1
(en)
|
2002-03-21 |
2003-10-02 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
SI1527100T1
(sl)
|
2002-03-29 |
2009-12-31 |
Schering Corp |
Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
|
CA2481074A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
US7357928B2
(en)
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
US7541150B2
(en)
|
2002-04-08 |
2009-06-02 |
University Of Louisville Research Foundation, Inc |
Method for the diagnosis and prognosis of malignant diseases
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
WO2003086458A1
(en)
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
JP4435575B2
(ja)
|
2002-04-18 |
2010-03-17 |
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド |
NF−κB誘導酵素の誘導体、その製法および使用
|
RU2004133765A
(ru)
|
2002-04-19 |
2005-06-27 |
ЗАЙМОДЖЕНЕТИКС Инк. (US) |
Рецептор цитокина
|
EP1513397B1
(en)
|
2002-05-17 |
2010-04-14 |
Kyowa Hakko Kirin Co., Ltd. |
Transgenic ungulates capable of human antibody production
|
EP1575491A4
(en)
*
|
2002-05-20 |
2006-09-27 |
Abgenix Inc |
TREATMENT OF RENAL CARCINOMA USING ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR
|
NZ537579A
(en)
|
2002-06-10 |
2006-10-27 |
Vaccinex Inc |
C35 peptide epitopes and their analogs
|
AU2003276679A1
(en)
|
2002-06-13 |
2003-12-31 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
CN100480260C
(zh)
|
2002-07-18 |
2009-04-22 |
克鲁塞尔荷兰公司 |
抗体混合物的重组生产
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
WO2004016733A2
(en)
|
2002-08-16 |
2004-02-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
EP2213685B1
(en)
|
2002-09-06 |
2013-11-27 |
Amgen Inc. |
Therapeutic anti-IL-1R1 monoclonal antibody
|
WO2004034988A2
(en)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
AU2003290689A1
(en)
|
2002-11-08 |
2004-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Transgenic ungulates having reduced prion protein activity and uses thereof
|
ES2345885T3
(es)
|
2002-11-15 |
2010-10-05 |
Novartis Vaccines And Diagnostics, Inc. |
Metodos para prevenir y tratar metastasis de cancer y perdida de hueso asociada con la metastasis de cancer.
|
MXPA05005921A
(es)
|
2002-12-02 |
2005-10-19 |
Abgenix Inc |
Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
|
US7276372B2
(en)
|
2002-12-20 |
2007-10-02 |
Pdl Biopharma, Inc. |
Antibodies against GPR64 and uses thereof
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
WO2004072263A2
(en)
|
2003-02-10 |
2004-08-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
|
AU2004212953B2
(en)
|
2003-02-14 |
2010-03-11 |
The Curators Of The University Of Missouri |
Contraceptive methods and compositions related to proteasomal interference
|
JP2007524362A
(ja)
|
2003-02-14 |
2007-08-30 |
サイグレス ディスカバリー, インコーポレイテッド |
癌における治療gpcr標的
|
ES2347959T3
(es)
|
2003-02-20 |
2010-11-26 |
Seattle Genetics, Inc. |
Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
|
JP2007525434A
(ja)
|
2003-03-19 |
2007-09-06 |
アブジェニックス インコーポレイテッド |
T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。
|
US7785829B2
(en)
|
2003-03-19 |
2010-08-31 |
Biogen Idec Ma, Inc. |
Nogo receptor binding protein
|
KR20110094361A
(ko)
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
CA2526398C
(en)
*
|
2003-05-21 |
2014-07-15 |
Medarex, Inc. |
Human monoclonal antibodies against bacillus anthracis protective antigen
|
NZ578591A
(en)
|
2003-05-30 |
2011-01-28 |
Agensys Inc |
Prostate stem cell antigen (PSCA) variants and subsequences thereof, namely SEQ ID NO: 6554
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
EP2457586A1
(en)
|
2003-06-27 |
2012-05-30 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
EP1644408A1
(en)
|
2003-07-15 |
2006-04-12 |
Barros Research Institute |
Eimeria tenella antigen for immunotherapy of coccidiosis
|
TW201319088A
(zh)
|
2003-07-18 |
2013-05-16 |
Amgen Inc |
對肝細胞生長因子具專一性之結合劑
|
EP1659918B1
(en)
|
2003-08-08 |
2009-01-14 |
Amgen Fremont Inc. |
Antibodies directed to parathyroid hormone (pth) and uses thereof
|
WO2005014795A2
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
US20050153392A1
(en)
*
|
2003-08-11 |
2005-07-14 |
Roland Buelow |
Transgenesis with humanized immunoglobulin loci
|
AU2004266242A1
(en)
*
|
2003-08-12 |
2005-03-03 |
Dyax Corp. |
Tie1-binding ligands
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
PL1703893T3
(pl)
|
2003-12-23 |
2012-09-28 |
Genentech Inc |
Nowe przeciwciała anty-IL 13 i ich zastosowania
|
AU2004304665B2
(en)
|
2003-12-24 |
2009-03-12 |
Novo Nordisk A/S |
Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
|
EP3476861A1
(en)
|
2004-01-07 |
2019-05-01 |
Novartis Vaccines and Diagnostics, Inc. |
M-csf-specific monoclonal antibody and uses thereof
|
JP4315982B2
(ja)
|
2004-01-09 |
2009-08-19 |
ファイザー インコーポレイティッド |
MAdCAMに対する抗体
|
AU2005211725B2
(en)
|
2004-02-09 |
2010-07-15 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
EP1729804A2
(en)
|
2004-03-19 |
2006-12-13 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
JP4879884B2
(ja)
|
2004-04-12 |
2012-02-22 |
メディミューン,エルエルシー |
抗−il−9抗体製剤及びその使用法
|
EP1749102A4
(en)
|
2004-04-22 |
2009-02-25 |
Kirin Pharma Kk |
TRANSGENIC ANIMALS AND USES THEREOF
|
NZ551627A
(en)
|
2004-05-28 |
2010-02-26 |
Agensys Inc |
Antibodies and related molecules that bind to PSCA proteins
|
DK2497492T3
(en)
|
2004-06-01 |
2018-11-26 |
Icahn School Med Mount Sinai |
Genetically modified swine influenza virus and its applications
|
US8921528B2
(en)
|
2004-06-01 |
2014-12-30 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
BRPI0512500A
(pt)
|
2004-06-24 |
2008-03-11 |
Biogen Idec Inc |
tratamento ou condições envolvendo desmielinação
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
EP1789805B1
(en)
|
2004-07-14 |
2010-09-15 |
The Regents of The University of California |
Biomarker for early detection of ovarian cancer
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
BRPI0513200A
(pt)
|
2004-07-16 |
2008-04-29 |
Pfizer Prod Inc |
uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
KR101151957B1
(ko)
|
2004-07-22 |
2012-06-01 |
로저 킹돈 크레이그 |
결합 분자
|
EP1789070B1
(en)
|
2004-08-03 |
2012-10-24 |
Biogen Idec MA Inc. |
Taj in neuronal function
|
AU2005267722B2
(en)
|
2004-08-04 |
2009-10-08 |
Amgen Inc. |
Antibodies to Dkk-1
|
CN101123994B
(zh)
|
2004-08-16 |
2012-11-14 |
夸克医药公司 |
Rtp801的抑制剂的治疗性用途
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
US20060045877A1
(en)
|
2004-08-30 |
2006-03-02 |
Goldmakher Viktor S |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
KR20070083899A
(ko)
|
2004-10-01 |
2007-08-24 |
메다렉스, 인코포레이티드 |
Cd30 양성 림프종의 치료 방법
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
AU2005299413A1
(en)
|
2004-10-22 |
2006-05-04 |
Revivicor, Inc. |
Ungulates with genetically modified immune systems
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
DE602005025525D1
(de)
|
2004-11-17 |
2011-02-03 |
Amgen Inc |
Vollständige humane monoklonale antikörper gegen il-13
|
WO2006055871A2
(en)
|
2004-11-19 |
2006-05-26 |
Biogen Idec Ma Inc. |
Treatment for multiple sclerosis
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
NZ555464A
(en)
|
2004-12-02 |
2010-03-26 |
Domantis Ltd |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
NZ556105A
(en)
*
|
2004-12-03 |
2009-12-24 |
Biogen Idec Inc |
Delaying or preventing onset of multiple sclerosis
|
WO2006061723A2
(en)
|
2004-12-06 |
2006-06-15 |
Kirin Beer Kabushiki Kaisha |
Human monoclonal antibodies to influenza m2 protein and methods of making and using same
|
CA2592249C
(en)
|
2004-12-20 |
2014-07-29 |
Amgen Fremont Inc. |
Binding proteins specific for human matriptase
|
NZ556029A
(en)
|
2004-12-21 |
2010-04-30 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
EP1851245B1
(en)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
CN101495498B
(zh)
|
2005-02-07 |
2013-09-18 |
基因信息公司 |
轻度骨关节炎生物标志物及其用途
|
JP5651285B2
(ja)
|
2005-02-15 |
2015-01-07 |
デューク ユニバーシティ |
抗cd19抗体および腫瘍学における使用
|
US20090124993A1
(en)
|
2005-02-17 |
2009-05-14 |
Burkly Linda C |
Treating neurological disorders
|
BRPI0607203A2
(pt)
|
2005-02-18 |
2009-08-25 |
Medarex Inc |
anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
AU2006218489B2
(en)
|
2005-03-02 |
2011-02-24 |
Biogen Ma Inc. |
KIM-1 antibodies for treatment of Th2-mediated conditions
|
EP1858545A2
(en)
|
2005-03-04 |
2007-11-28 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
WO2006096488A2
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising human igg2 antibody and chelating agent
|
ES2440953T3
(es)
|
2005-03-31 |
2014-01-31 |
The General Hospital Corporation |
Modulación de la actividad de HGF/HGFR para tratar un linfedema
|
EP2444099A1
(en)
|
2005-03-31 |
2012-04-25 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161P2F10B proteins
|
DK2645106T3
(en)
|
2005-04-04 |
2017-10-02 |
Biogen Ma Inc |
Methods for Evaluating an Immune Response to a Therapeutic Agent
|
US20090214536A1
(en)
|
2005-04-07 |
2009-08-27 |
Guoying Yu |
CACNA1E in Cancer Diagnosis, Detection and Treatment
|
EP1871911A2
(en)
|
2005-04-07 |
2008-01-02 |
Chiron Corporation |
Cancer-related genes (prlr)
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
WO2006113643A2
(en)
*
|
2005-04-20 |
2006-10-26 |
Amgen Fremont Inc. |
High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
|
AU2006239860B2
(en)
|
2005-04-25 |
2012-01-19 |
Amgen Fremont Inc. |
Antibodies to myostatin
|
CA2604357C
(en)
|
2005-04-26 |
2012-01-17 |
Pfizer Inc. |
P-cadherin antibodies
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
AU2006244445B2
(en)
|
2005-05-05 |
2013-04-18 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
JP5339901B2
(ja)
|
2005-05-10 |
2013-11-13 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
炎症傷害の処置および評価
|
JP2008545712A
(ja)
|
2005-05-25 |
2008-12-18 |
キュアーディーエム、インク. |
ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
|
MEP35408A
(en)
|
2005-05-27 |
2011-02-10 |
Biogen Idec Inc |
Tweak binding antibodies
|
WO2006138219A2
(en)
|
2005-06-13 |
2006-12-28 |
Biogen Idec Ma Inc. |
Methods of diagnosis / prognosis of inflammatory conditions
|
EP1893647A2
(en)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
HUE042561T2
(hu)
|
2005-06-30 |
2019-07-29 |
Janssen Biotech Inc |
Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
|
BRPI0613387A2
(pt)
|
2005-07-08 |
2011-01-11 |
Biogen Idec Inc |
anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
|
EP2397496A3
(en)
|
2005-07-18 |
2013-05-29 |
Amgen, Inc |
Human anti-B7RP1 neutralizing antibodies
|
WO2007016285A2
(en)
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
DK2573114T3
(en)
|
2005-08-10 |
2016-07-04 |
Macrogenics Inc |
The identification and production of antibodies with variant Fc regions, and methods of using same
|
EP2500359A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
WO2007024715A2
(en)
|
2005-08-19 |
2007-03-01 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
EA201300320A1
(ru)
|
2005-09-07 |
2014-02-28 |
Эмджен Фримонт Инк. |
Моноклональные антитела человека к киназе-1, подобной рецептору активина
|
JP2009508494A
(ja)
|
2005-09-16 |
2009-03-05 |
ラプトール ファーマシューティカル インコーポレイテッド |
Crを含むタンパク質に対して特異的な受容体−結合タンパク質(rap)変異体を含む組成物およびその使用
|
CA2624562A1
(en)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
|
CA2626604A1
(en)
|
2005-10-21 |
2007-04-26 |
Genenews Inc. |
Method and apparatus for correlating levels of biomarker products with disease
|
PE20070796A1
(es)
*
|
2005-10-24 |
2007-08-15 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
CA2628451A1
(en)
|
2005-11-04 |
2007-05-18 |
Biogen Idec Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
UA99591C2
(ru)
|
2005-11-04 |
2012-09-10 |
Дженентек, Инк. |
Применение ингибиторов пути комплемента для лечения глазных болезней
|
CA2628238A1
(en)
|
2005-11-07 |
2007-05-18 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
AU2006315580A1
(en)
|
2005-11-10 |
2007-05-24 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
|
EP1951906B1
(en)
|
2005-11-10 |
2010-12-22 |
Bristol-Myers Squibb Pharma Company |
Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
|
PT1951759E
(pt)
|
2005-11-12 |
2010-04-01 |
Lilly Co Eli |
Anticorpos anti-egfr
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
ES2409835T3
(es)
|
2005-11-28 |
2013-06-28 |
Zymogenetics, Inc. |
Antagonistas de IL-21
|
US8691224B2
(en)
|
2005-11-30 |
2014-04-08 |
Abbvie Inc. |
Anti-Aβ globulomer 5F7 antibodies
|
KR20180058863A
(ko)
|
2005-11-30 |
2018-06-01 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
EP2251034B1
(en)
|
2005-12-02 |
2018-02-14 |
Icahn School of Medicine at Mount Sinai |
Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
|
EP1965827B1
(en)
|
2005-12-02 |
2015-02-25 |
Biogen Idec MA Inc. |
Treatment of conditions involving demyelination
|
CA2630157C
(en)
|
2005-12-07 |
2018-01-09 |
Medarex, Inc. |
Ctla-4 antibody dosage escalation regimens
|
US20070134249A1
(en)
*
|
2005-12-08 |
2007-06-14 |
Genitope Corporation |
Combination therapy and antibody panels
|
KR101372690B1
(ko)
|
2005-12-13 |
2014-03-17 |
아스트라제네카 아베 |
인슐린 유사 성장 인자에 특이적인 결합 단백질 및 이의용도
|
ES2535856T3
(es)
|
2005-12-15 |
2015-05-18 |
Genentech, Inc. |
Métodos y composiciones para dirigirse a la poliubiquitina
|
CA2633211A1
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
CA2635588C
(en)
|
2005-12-30 |
2015-11-10 |
Dyax Corp. |
Metalloproteinase binding proteins
|
CA2636288C
(en)
|
2006-01-10 |
2015-02-24 |
Zymogenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
|
RU2520088C2
(ru)
|
2006-01-12 |
2014-06-20 |
Алексион Фармасьютикалз, Инк. |
Антитела к ох-2/сd200 и их применение
|
TWI428143B
(zh)
|
2006-01-18 |
2014-03-01 |
Gen Hospital Corp |
增加淋巴功能之方法
|
NL2000439C2
(nl)
|
2006-01-20 |
2009-03-16 |
Quark Biotech |
Therapeutische toepassingen van inhibitoren van RTP801.
|
RU2435784C2
(ru)
|
2006-01-25 |
2011-12-10 |
Эрасмус Юниверсити Медикал Сентр Роттердам |
Получение антител из одних тяжелых цепей в трансгенных животных
|
EP1981902B1
(en)
|
2006-01-27 |
2015-07-29 |
Biogen MA Inc. |
Nogo receptor antagonists
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
EP2311477B1
(en)
|
2006-03-20 |
2014-07-09 |
Japan Science and Technology Agency |
Use of ip3 receptor-binding protein for controlling phosphatidylinositol metabolism
|
WO2007111661A2
(en)
|
2006-03-20 |
2007-10-04 |
Xoma Technology Ltd. |
Human antibodies specific for gastrin materials and methods
|
EP2003960B1
(en)
|
2006-03-31 |
2015-06-10 |
E. R. Squibb & Sons, L.L.C. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
BRPI0709481A2
(pt)
|
2006-04-07 |
2011-07-19 |
Government Of The Us Secretary Dept Of Health And Human Services |
anticorpo monoclonal isolado, anticorpo monoclonal humano isolado, composição farmacêutica, anticorpo anti-igf-i e anti-igf-ii recombinante isolado ou fragmento de ligação ao antìgeno do mesmo, método para detectar o fator i e o fator ii de crescimento insulina humana em uma amostra, método para dectetar o fator i de crescimento insulina humana em uma amostra, ácido nucléico isolado, célula recombinante , célula hospedeira ,método para preparar um anticorpo, método para preparar um anticorpo, método para tratar uma doença neoplásica em um indivìduo mamìfero, método para diagnosticar doença neoplásica em um indivìduo mamìfero e método para classificar um composto candidato a fármaco
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
MX2008013121A
(es)
|
2006-04-13 |
2009-03-25 |
Novartis Vaccines & Diagnostic |
Metodo para tratar, diagnosticar o detectar cancer.
|
CN105381459A
(zh)
|
2006-05-25 |
2016-03-09 |
比奥根Ma公司 |
治疗中风的方法
|
WO2007140371A2
(en)
|
2006-05-30 |
2007-12-06 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
AR061171A1
(es)
|
2006-06-02 |
2008-08-06 |
Aveo Pharmaceuticals Inc |
Proteinas de union al factor de crecimiento de hepatocitos (fch)
|
MX2008015138A
(es)
|
2006-06-02 |
2009-01-28 |
Aveo Pharmaceuticals Inc |
Proteinas de union al factor de crecimiento de hepatocitos (fch).
|
AU2007319672B2
(en)
|
2006-06-06 |
2011-06-30 |
Genentech, Inc. |
Anti-DLL4 antibodies and methods using same
|
EP2037961B1
(en)
|
2006-06-14 |
2015-11-11 |
MacroGenics, Inc. |
Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
US8304384B2
(en)
|
2006-06-28 |
2012-11-06 |
Yeda Research And Development Co., Ltd |
Caspase-8 and inflammation, infection and wound healing
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EP2046383B1
(en)
|
2006-07-04 |
2014-11-19 |
Genmab A/S |
Cd20 binding molecules for the treatment of copd
|
NZ574046A
(en)
|
2006-07-13 |
2012-09-28 |
Univ Iowa Res Found |
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
|
KR101528939B1
(ko)
|
2006-07-18 |
2015-06-15 |
사노피 |
암 치료를 위한 epha2에 대한 길항제 항체
|
CN103524619B
(zh)
|
2006-08-03 |
2016-10-05 |
阿斯利康(瑞典)有限公司 |
针对αVβ6的抗体及其应用
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
LT2511301T
(lt)
|
2006-08-04 |
2018-04-10 |
Medimmune Limited |
Žmogaus antikūnas prieš erbb2
|
JP5406027B2
(ja)
|
2006-08-04 |
2014-02-05 |
ノバルティス アーゲー |
EphB3特異的抗体およびその使用
|
AR062435A1
(es)
|
2006-08-18 |
2008-11-05 |
Xoma Technology Ltd |
Anticuerpo especifico prlr (receptor de prolactina) y sus usos
|
EP2455404B1
(en)
|
2006-08-22 |
2016-02-10 |
Novo Nordisk A/S |
Anti-C5AR antibodies with improved properties
|
EP2064243A2
(en)
|
2006-08-28 |
2009-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic human light-specific human monoclonal antibodies
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
CN101506235B
(zh)
|
2006-09-01 |
2012-07-25 |
人类多细胞株治疗学公司 |
人或人源化免疫球蛋白在非人转基因动物中增强的表达
|
US20090053210A1
(en)
|
2006-09-01 |
2009-02-26 |
Roland Buelow |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
MY188368A
(en)
|
2006-09-08 |
2021-12-06 |
Abbott Lab |
Interleukin-13 binding proteins
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
US9492518B2
(en)
|
2006-10-04 |
2016-11-15 |
Dana-Farber Cancer Institute, Inc. |
Tumor immunity
|
BRPI0719250A2
(pt)
*
|
2006-10-12 |
2015-06-16 |
Wyeth Corp |
Métodos e composições com opalescência reduzida.
|
EP2407548A1
(en)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Molecules with reduced half-lives, compositions and uses thereof
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
PT2845866T
(pt)
|
2006-10-27 |
2017-08-09 |
Genentech Inc |
Anticorpos e imunoconjugados e utilizações dos mesmos
|
ES2541546T3
(es)
*
|
2006-11-03 |
2015-07-21 |
Wyeth Llc |
Sustancias que inhiben la glucólisis en cultivo celular
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
US20080199475A1
(en)
|
2006-11-27 |
2008-08-21 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
MX2009006034A
(es)
|
2006-12-07 |
2009-10-12 |
Novartis Ag |
Anticuerpos antagonistas contra ephb3.
|
DK2121751T3
(en)
|
2006-12-08 |
2017-04-24 |
Lexicon Pharmaceuticals Inc |
Monoclonal antibodies to ANGPTL3
|
EP2099827B1
(en)
|
2006-12-18 |
2018-11-21 |
Genentech, Inc. |
Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
|
EP3124045A3
(en)
|
2006-12-20 |
2017-05-03 |
Xoma (Us) Llc |
Treatment of il-1 beta related diseases
|
SI2436696T1
(sl)
|
2007-01-05 |
2017-10-30 |
University Of Zurich |
Anti-beta-amiloidno protitelo in načini njegove uporabe
|
DK2068887T3
(da)
|
2007-01-09 |
2014-05-19 |
Biogen Idec Inc |
SP35-antistoffer og anvendelser heraf
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
WO2008088823A2
(en)
|
2007-01-16 |
2008-07-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
US7834154B2
(en)
|
2007-02-09 |
2010-11-16 |
Genentech, Inc. |
Anti-ROBO4 antibodies and uses therefor
|
WO2008101184A2
(en)
|
2007-02-16 |
2008-08-21 |
The Board Of Trustees Of Southern Illinois University |
Arl-1 specific antibodies
|
US8685666B2
(en)
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
CA2676790A1
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
AU2008217488B2
(en)
*
|
2007-02-22 |
2012-07-19 |
Roger M. Simonson |
Magnetic filter and magnetic filtering assembly
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
EP2132573B1
(en)
|
2007-03-02 |
2014-04-23 |
Genentech, Inc. |
Predicting response to a her dimerisation inhbitor based on low her3 expression
|
SI2412828T1
(sl)
|
2007-03-13 |
2013-10-30 |
Amgen Inc. |
Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr
|
HUE033695T2
(en)
|
2007-03-13 |
2017-12-28 |
Amgen Inc |
K-RAS mutations and anti-EGFR antibody therapy
|
WO2008112988A2
(en)
|
2007-03-14 |
2008-09-18 |
Novartis Ag |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
DK2125894T3
(en)
|
2007-03-22 |
2019-03-18 |
Biogen Ma Inc |
BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, SPECIFICALLY BINDING CD154 AND APPLICATIONS THEREOF
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
RU2476442C2
(ru)
*
|
2007-03-29 |
2013-02-27 |
Эббот Лэборетриз |
Кристаллические антитела против il-12 человека
|
US20100209434A1
(en)
|
2007-03-30 |
2010-08-19 |
Medimmune, Llc |
Antibody formulation
|
BRPI0809677A2
(pt)
|
2007-04-02 |
2014-10-07 |
Pfizer |
Anticorpos anti-ige
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
NZ599278A
(en)
|
2007-05-14 |
2013-12-20 |
Medimmune Llc |
Methods of reducing eosinophil levels
|
AU2008254582A1
(en)
|
2007-05-21 |
2008-11-27 |
Genentech, Inc. |
Methods and compositions for identifying and treating lupus
|
KR101661357B1
(ko)
|
2007-06-01 |
2016-09-29 |
오픈 모노클로날 테크놀로지, 인코포레이티드 |
내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
|
PL2171090T3
(pl)
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Markery ekspresji genów odporności guza na leczenie hamujące HER2
|
DK2170390T3
(en)
|
2007-06-14 |
2019-01-21 |
Biogen Ma Inc |
NATALIZUMABANTISTIC FORMULATIONS
|
EP3424951A1
(en)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
DK3597659T3
(da)
|
2007-07-09 |
2023-04-03 |
Genentech Inc |
Forhindring af disulfidbindingsreduktion under rekombinant produktion af polypeptider
|
DK2185719T3
(en)
|
2007-08-02 |
2014-02-17 |
Novimmune Sa |
ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
SG10201500328QA
(en)
|
2007-08-21 |
2015-03-30 |
Amgen Inc |
Human c-fms antigen binding proteins
|
EP2615114B1
(en)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
CN111909273B
(zh)
|
2007-08-29 |
2024-03-26 |
塞诺菲-安万特股份有限公司 |
人源化的抗-cxcr5抗体、其衍生物及它们的应用
|
MY165889A
(en)
|
2007-08-30 |
2018-05-18 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
US20110052569A1
(en)
|
2007-09-06 |
2011-03-03 |
University Of Washington |
Molecules and methods for treatment of diabetes
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
RU2504551C2
(ru)
|
2007-09-26 |
2014-01-20 |
УЗ ФАРМА ГмбХ |
Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
|
WO2009043049A2
(en)
|
2007-09-27 |
2009-04-02 |
Amgen Inc. |
Pharmaceutical formulations
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
ES2557352T3
(es)
|
2007-11-05 |
2016-01-25 |
Medimmune, Llc |
Métodos de tratamiento de la esclerodermia
|
BRPI0820707A2
(pt)
|
2007-11-07 |
2015-06-16 |
Genentech Inc |
Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40
|
PT2514436T
(pt)
|
2007-11-07 |
2018-03-21 |
Genentech Inc |
Il-22 para utilização no tratamento de distúrbios microbianos
|
MY155621A
(en)
|
2007-11-12 |
2015-11-13 |
U3 Pharma Gmbh |
Axl antibodies
|
EP2219602A1
(en)
|
2007-11-15 |
2010-08-25 |
Amgen, Inc |
Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
|
CA2705923A1
(en)
|
2007-11-16 |
2009-05-22 |
Nuvelo, Inc. |
Antibodies to lrp6
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
PL2391650T3
(pl)
|
2007-12-20 |
2015-03-31 |
Xoma Us Llc |
Sposoby leczenia dny
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
ES2543201T3
(es)
|
2007-12-26 |
2015-08-17 |
Biotest Ag |
Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138
|
HUE024291T2
(en)
|
2007-12-26 |
2016-01-28 |
Biotest Ag |
Immunoconjugates and Applications for CD138
|
RU2537265C2
(ru)
|
2007-12-26 |
2014-12-27 |
Биотест Аг |
Агенты против клетки-мишени, нацеленные на cd138, и их применение
|
US9011864B2
(en)
|
2007-12-26 |
2015-04-21 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
WO2009092011A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
JP5701064B2
(ja)
|
2008-01-25 |
2015-04-15 |
アムジエン・インコーポレーテツド |
フェロポーチン抗体およびその使用方法
|
KR101666229B1
(ko)
|
2008-02-08 |
2016-10-14 |
메디뮨 엘엘씨 |
Fc 리간드 친화성이 감소된 항-IFNAR1 항체
|
IL189408A0
(en)
|
2008-02-10 |
2009-02-11 |
Yeda Res & Dev |
Siva3, its preparation and pharmaceutical compositions containing it
|
JP2011515073A
(ja)
|
2008-02-20 |
2011-05-19 |
ジーツー インフラメイション プロプライエタリー リミテッド |
ヒト化抗C5aR抗体
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
TW201513883A
(zh)
|
2008-03-18 |
2015-04-16 |
Abbvie Inc |
治療牛皮癬的方法
|
EP2260102A1
(en)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
NZ588853A
(en)
|
2008-03-31 |
2013-07-26 |
Genentech Inc |
Compositions and methods for treating and diagnosing asthma
|
CA2721231C
(en)
|
2008-04-14 |
2015-10-06 |
Innovative Targeting Solutions Inc. |
Sequence diversity generation in immunoglobulins
|
US8604179B2
(en)
|
2008-04-25 |
2013-12-10 |
Toray Industries, Inc. |
Nucleic acid comprising chimeric gene derived from hepatitis C virus
|
KR101837329B1
(ko)
|
2008-04-25 |
2018-03-09 |
다이액스 코포레이션 |
Fcrn에 대한 항체 및 이들의 용도
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
ES2487846T3
(es)
|
2008-05-01 |
2014-08-25 |
Amgen, Inc. |
Anticuerpos anti-hepcindina y métodos de uso
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
WO2009136382A2
(en)
|
2008-05-09 |
2009-11-12 |
Abbott Gmbh & Co. Kg |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
JP2011523853A
(ja)
|
2008-06-03 |
2011-08-25 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリン及びその使用
|
ES2595362T3
(es)
|
2008-06-16 |
2016-12-29 |
Patrys Limited |
Anticuerpos LM, fragmentos funcionales, antígeno diana LM-1 y métodos para prepararlos y usarlos
|
CA2729012A1
(en)
|
2008-06-27 |
2009-12-30 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
RU2559525C2
(ru)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Белки, связывающие простагландин е2, и их применение
|
SG192489A1
(en)
|
2008-07-08 |
2013-08-30 |
Abbott Lab |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
NZ590605A
(en)
|
2008-07-09 |
2012-11-30 |
Biogen Idec Inc |
Compositions comprising antibodies to lingo or fragments thereof
|
WO2010009271A2
(en)
|
2008-07-15 |
2010-01-21 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
KR20160116056A
(ko)
|
2008-08-14 |
2016-10-06 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
항-il-12/il-23 항체
|
SG193216A1
(en)
|
2008-08-18 |
2013-09-30 |
Amgen Fremont Inc |
Antibodies to ccr2
|
WO2010027981A1
(en)
|
2008-09-03 |
2010-03-11 |
Genentech, Inc. |
Multispecific antibodies
|
BRPI0823049A2
(pt)
|
2008-09-07 |
2015-06-16 |
Glyconex Inc |
Anticorpos para glicoesfingolipídeos tipo 1 anti-estendidos, derivados dos mesmos e uso.
|
KR20110057244A
(ko)
|
2008-09-19 |
2011-05-31 |
메디뮨 엘엘씨 |
Dll4에 대한 항체 및 이의 용도
|
US20100075329A1
(en)
|
2008-09-23 |
2010-03-25 |
O'toole Margot |
Methods for predicting production of activating signals by cross-linked binding proteins
|
WO2010039900A2
(en)
|
2008-09-30 |
2010-04-08 |
Aliva Biopharmaceuticals, Inc. |
Non-human mammals for the production of chimeric antibodies
|
JP5913980B2
(ja)
|
2008-10-14 |
2016-05-11 |
ジェネンテック, インコーポレイテッド |
免疫グロブリン変異体及びその用途
|
EP2349329A4
(en)
|
2008-10-14 |
2012-10-31 |
Dyax Corp |
USE OF IGF-II / IGF-II BINDING FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS ASSOCIATED WITH LUNG FIBROSIS
|
AU2009308422B2
(en)
|
2008-10-24 |
2017-01-05 |
The Government of the United States of America as represented by The Secretary, Department of Health and Human Services, Center for Disease Control and Prevention |
Human Ebola virus species and compositions and methods thereof
|
WO2010051288A1
(en)
|
2008-10-27 |
2010-05-06 |
Revivicor, Inc. |
Immunocompromised ungulates
|
MX2011004558A
(es)
|
2008-10-29 |
2011-06-01 |
Wyeth Llc |
Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
|
MX345226B
(es)
|
2008-10-29 |
2017-01-20 |
Ablynx Nv |
Formulaciones de moleculas de union a antigeno de dominio sencillo.
|
WO2010052288A1
(en)
|
2008-11-07 |
2010-05-14 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
CA2742802C
(en)
|
2008-11-10 |
2019-11-26 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
US20140086919A1
(en)
*
|
2012-09-24 |
2014-03-27 |
Herbert Y. Lin |
Methods and compositons for regulating iron homeostasis by modulation of bmp-6
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
CN102301235B
(zh)
*
|
2008-11-28 |
2014-11-19 |
Abbvie公司 |
稳定的抗体组合物和用于稳定其的方法
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
CN114835812A
(zh)
|
2008-12-09 |
2022-08-02 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
CN112680475A
(zh)
*
|
2008-12-18 |
2021-04-20 |
伊拉兹马斯大学鹿特丹医学中心 |
表达人源化抗体的非人转基因动物及其用途
|
JP5734201B2
(ja)
|
2008-12-19 |
2015-06-17 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディ及びその使用
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
WO2010075548A2
(en)
|
2008-12-23 |
2010-07-01 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
WO2010072740A2
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
|
WO2010078526A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
WO2010082134A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
US20130122052A1
(en)
|
2009-01-20 |
2013-05-16 |
Homayoun H. Zadeh |
Antibody mediated osseous regeneration
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2010091182A2
(en)
|
2009-02-04 |
2010-08-12 |
Molecular Innovations |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
|
US8309530B2
(en)
|
2009-02-04 |
2012-11-13 |
Washington State University |
Compositions and methods for modulating ghrelin-mediated conditions
|
US20110014190A1
(en)
|
2009-02-12 |
2011-01-20 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
PE20121094A1
(es)
|
2009-03-05 |
2012-09-13 |
Abbvie Inc |
Proteinas de union a il-17
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
TWI461211B
(zh)
|
2009-03-20 |
2014-11-21 |
Genentech Inc |
抗-her抗體
|
CA3018235C
(en)
|
2009-03-20 |
2021-01-12 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
RU2542394C2
(ru)
|
2009-03-24 |
2015-02-20 |
ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. |
Гуманизированные антитела против light и их применение
|
EP2413962A1
(en)
|
2009-03-30 |
2012-02-08 |
Mount Sinai School of Medicine |
Influenza virus vaccines and uses thereof
|
KR101766927B1
(ko)
|
2009-04-01 |
2017-08-09 |
제넨테크, 인크. |
인슐린 저항성 장애의 치료
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
WO2010117057A1
(ja)
|
2009-04-10 |
2010-10-14 |
協和発酵キリン株式会社 |
抗tim-3抗体を用いた血液腫瘍治療法
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
US8722860B2
(en)
|
2009-04-16 |
2014-05-13 |
Abbvie Biotherapeutics Inc. |
Anti-TNF-α antibodies and their uses
|
AU2010236257A1
(en)
*
|
2009-04-17 |
2011-11-03 |
Biogen Idec Ma Inc. |
Compositions and methods to treat acute myelogenous leukemia
|
AU2010236168B2
(en)
|
2009-04-18 |
2015-08-13 |
Genentech, Inc. |
Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
|
KR101732201B1
(ko)
|
2009-04-27 |
2017-05-02 |
교와 핫꼬 기린 가부시키가이샤 |
혈액 종양 치료를 목적으로 하는 항IL-3Rα 항체
|
ES2725356T3
(es)
|
2009-04-29 |
2019-09-23 |
Henry M Jackson Found Advancement Military Medicine Inc |
Anticuerpos monoclonales de ERG2 y su uso terapéutico
|
EP2427203B1
(en)
|
2009-05-05 |
2018-10-17 |
Novimmune S.A. |
Anti-il-17f antibodies and use thereof
|
AU2010254136B2
(en)
|
2009-05-26 |
2016-09-29 |
Mount Sinai School Of Medicine |
Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
EP2443150B1
(en)
|
2009-06-17 |
2015-01-21 |
AbbVie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP3871498A1
(en)
|
2009-07-08 |
2021-09-01 |
Kymab Limited |
Animal models and therapeutic molecules
|
CN102481380A
(zh)
|
2009-07-09 |
2012-05-30 |
霍夫曼-拉罗奇有限公司 |
体内肿瘤血管系统成像
|
WO2011006001A1
(en)
|
2009-07-09 |
2011-01-13 |
Genentech, Inc. |
Animal model for the evaluation of adjuvant therapies of cancer
|
KR20120106935A
(ko)
|
2009-07-13 |
2012-09-27 |
제넨테크, 인크. |
암의 치료를 위한 진단 방법 및 조성물
|
WO2011014504A1
(en)
|
2009-07-27 |
2011-02-03 |
Mount Sinai School Of Medicine Of New York University |
Recombinant influenza virus vectors and uses thereof
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
EP2459585A1
(en)
|
2009-07-30 |
2012-06-06 |
Mount Sinai School of Medicine |
Influenza viruses and uses thereof
|
US20110027275A1
(en)
|
2009-07-31 |
2011-02-03 |
Napoleone Ferrara |
Inhibition of tumor metastasis
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
ES2793348T3
(es)
|
2009-08-11 |
2020-11-13 |
Hoffmann La Roche |
Producción de proteínas en medios de cultivo celular libres de glutamina
|
JP5762408B2
(ja)
|
2009-08-13 |
2015-08-12 |
クルセル ホランド ベー ヴェー |
ヒト呼吸器合胞体ウイルス(rsv)に対する抗体および使用方法
|
EP2464220A4
(en)
|
2009-08-13 |
2014-05-07 |
Crystal Bioscience Inc |
Transgenic animal for the production of antibodies with minimal complementarity-determining regions
|
US20110117083A1
(en)
|
2009-08-14 |
2011-05-19 |
Genentech, Inc. |
Biological markers for monitoring patient response to vegf antagonists
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
EP2470568A2
(en)
|
2009-08-29 |
2012-07-04 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
SG178602A1
(en)
|
2009-09-01 |
2012-04-27 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
CA2772929A1
(en)
|
2009-09-03 |
2011-03-11 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
JO3246B1
(ar)
|
2009-09-09 |
2018-03-08 |
Regeneron Pharma |
اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
|
WO2011032013A1
(en)
|
2009-09-11 |
2011-03-17 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
AU2010291927A1
(en)
|
2009-09-14 |
2012-04-12 |
AbbVie Deutschland GmbH & Co. KG |
Methods for treating psoriasis
|
ES2530732T3
(es)
|
2009-09-17 |
2015-03-05 |
Hoffmann La Roche |
Procedimientos de diagnóstico para el cáncer de pulmón
|
EP2480573A1
(en)
|
2009-09-22 |
2012-08-01 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
JP5885664B2
(ja)
|
2009-09-25 |
2016-03-15 |
ゾーマ テクノロジー リミテッド |
スクリーニング法
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
KR101108642B1
(ko)
|
2009-09-29 |
2012-02-09 |
주식회사 녹십자 |
표피 성장 인자 수용체에 특이적으로 결합하는 항체
|
BR112012007252A2
(pt)
|
2009-09-30 |
2020-08-11 |
Genentech Inc |
uso de um antagonista específico de notch3, anticorpo e método para identificar um câncer
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス,インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すFc領域含有ポリペプチドおよびその使用法
|
CA2777055C
(en)
|
2009-10-07 |
2021-04-06 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring lupus
|
CA2776756A1
(en)
|
2009-10-11 |
2011-04-14 |
Biogen Idec Ma Inc. |
Anti-vla-4 related assays
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
WO2011056606A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CA2777825A1
(en)
|
2009-10-28 |
2011-05-19 |
Abbott Biotherapeutics Corp. |
Anti-egfr antibodies and their uses
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
EP2496243A2
(en)
|
2009-11-04 |
2012-09-12 |
Erasmus University Medical Center Rotterdam |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
GB0919751D0
(en)
|
2009-11-11 |
2009-12-30 |
King S College Hospital Nhs Fo |
Conjugate molecule
|
PT2719708T
(pt)
|
2009-11-13 |
2018-01-16 |
Daiichi Sankyo Europe Gmbh |
Material e métodos para tratamento ou prevenção de doenças associadas a her-3
|
WO2011062997A2
(en)
|
2009-11-17 |
2011-05-26 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
AU2010321832B2
(en)
*
|
2009-11-20 |
2014-08-14 |
Amgen Inc. |
Anti-Orai1 antigen binding proteins and uses thereof
|
HUE037159T2
(hu)
|
2009-11-24 |
2018-08-28 |
Medimmune Ltd |
Targetált kötõdõ ágensek B7-H1 ellen
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
CA2780069C
(en)
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
US8937159B2
(en)
|
2009-12-16 |
2015-01-20 |
Abbvie Biotherapeutics Inc. |
Anti-HER2 antibodies and their uses
|
TR201808011T4
(tr)
|
2009-12-21 |
2018-06-21 |
Regeneron Pharma |
Hümanize fc gama r fareleri.
|
RU2017102553A
(ru)
|
2009-12-21 |
2018-12-19 |
Дженентек, Инк. |
Состав, содержащий антитело
|
ES2585350T3
(es)
|
2009-12-23 |
2016-10-05 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti Bv8 y usos de los mismos
|
ES2688093T3
(es)
|
2010-01-06 |
2018-10-30 |
Dyax Corp. |
Proteínas de unión a calicreína plasmática
|
KR20130005264A
(ko)
|
2010-01-11 |
2013-01-15 |
알렉시온 파마슈티칼스, 인코포레이티드 |
항-cd200 항체들로 치료한 사람에게서 면역조절 효과의 생체지표들
|
LT2523688T
(lt)
|
2010-01-15 |
2018-03-12 |
Kirin-Amgen, Inc. |
Antikūno kompozicija ir terapiniai režimai
|
US8865462B2
(en)
|
2010-01-20 |
2014-10-21 |
Crystal Bioscience Inc. |
Sustained culture of avian gonocytes
|
ES2603559T5
(es)
|
2010-02-08 |
2021-02-22 |
Regeneron Pharma |
Cadena ligera común de ratón
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
JP5841072B2
(ja)
|
2010-02-10 |
2016-01-06 |
イミュノジェン・インコーポレーテッド |
Cd20抗体およびその使用
|
CA2789436C
(en)
*
|
2010-02-12 |
2020-10-06 |
The Regents Of The University Of California |
Upar binding agents and methods of use thereof
|
WO2011103453A2
(en)
|
2010-02-18 |
2011-08-25 |
Mount Sinai School Of Medicine |
Vaccines for use in the prophylaxis and treatment of influenza virus disease
|
SG10201501562VA
(en)
|
2010-03-02 |
2015-04-29 |
Abbvie Inc |
Therapeutic dll4 binding proteins
|
EP2542578A1
(en)
|
2010-03-05 |
2013-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Smoc1, tenascin-c and brain cancers
|
KR20130075732A
(ko)
|
2010-03-30 |
2013-07-05 |
마운트 시나이 스쿨 오브 메디슨 |
인플루엔자 바이러스 백신 및 이의 용도
|
KR102117771B1
(ko)
|
2010-03-31 |
2020-06-02 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
US8987419B2
(en)
|
2010-04-15 |
2015-03-24 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
WO2011130417A2
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
|
CN103038257A
(zh)
|
2010-04-16 |
2013-04-10 |
比奥根艾迪克Ma公司 |
抗vla-4抗体
|
EP2561076A1
(en)
|
2010-04-19 |
2013-02-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
ES2552954T3
(es)
|
2010-04-30 |
2015-12-03 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
|
IL208820A0
(en)
|
2010-10-19 |
2011-01-31 |
Rachel Teitelbaum |
Biologic female contraceptives
|
DK2568976T3
(en)
|
2010-05-10 |
2016-01-11 |
Academia Sinica |
Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
|
US20110293629A1
(en)
|
2010-05-14 |
2011-12-01 |
Bastid Jeremy |
Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
|
UY33386A
(es)
|
2010-05-14 |
2011-12-30 |
Abbott Laboratoires |
Proteínas de unión a il-1
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
KR20130098165A
(ko)
|
2010-06-03 |
2013-09-04 |
제넨테크, 인크. |
항체 및 면역접합체의 이뮤노-pet 영상화 및 그의 용도
|
EP2580239A1
(en)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
EP2582722A4
(en)
|
2010-06-19 |
2013-12-18 |
Sloan Kettering Inst Cancer |
ANTIBODIES AGAINST GD2
|
RU2601297C2
(ru)
*
|
2010-06-22 |
2016-10-27 |
Ридженерон Фармасьютикалз, Инк. |
Мыши, экспрессирующие гибридную легкую цепь иммуноглобулина
|
USRE49339E1
(en)
|
2010-06-22 |
2022-12-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the C3D fragment of complement component 3
|
AU2011268780A1
(en)
|
2010-06-25 |
2013-02-07 |
Aston University |
Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
|
WO2012012141A1
(en)
|
2010-06-30 |
2012-01-26 |
Amgen Inc. |
Scnn1a/tnfrsf1a fusion proteins in cancer
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN103097412B
(zh)
|
2010-07-09 |
2016-08-10 |
克鲁塞尔荷兰公司 |
抗人呼吸道合胞病毒(rsv)抗体以及使用方法
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
WO2012007880A2
(en)
|
2010-07-16 |
2012-01-19 |
Ablynx Nv |
Modified single domain antigen binding molecules and uses thereof
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
BR112013001431A2
(pt)
|
2010-07-19 |
2016-05-31 |
Hoffmann La Roche |
método de identificação de pacientes com maior probabilidade de reação a terapia anticâncer
|
GB201012420D0
(en)
|
2010-07-23 |
2010-09-08 |
Univ Erasmus Medical Ct |
Foetal heamoglobin inhibitor
|
GB201012410D0
(en)
|
2010-07-23 |
2010-09-08 |
Medical Res Council |
Intracellular immunity
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
KR20130097156A
(ko)
|
2010-07-26 |
2013-09-02 |
트리아니, 인코포레이티드 |
트랜스제닉 동물 및 이의 사용 방법
|
HUE041590T2
(hu)
|
2010-07-29 |
2019-05-28 |
Eleven Biotherapeutics Inc |
Kiméra IL-1 receptor I agonisták és antagonisták
|
CN103154025B
(zh)
|
2010-08-02 |
2015-07-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
KR102434557B1
(ko)
|
2010-08-02 |
2022-08-23 |
리제너론 파아마슈티컬스, 인크. |
Vl 도메인을 포함하는 결합 단백질을 생성하는 마우스
|
MX341579B
(es)
|
2010-08-03 |
2016-08-25 |
Abbvie Inc * |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
CA2815154A1
(en)
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
EA201370030A1
(ru)
|
2010-08-10 |
2013-06-28 |
Амген Инк. |
Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
PL3333188T3
(pl)
|
2010-08-19 |
2022-05-09 |
Zoetis Belgium S.A. |
Przeciwciała anty-ngf i ich zastosowanie
|
AU2011293253B2
(en)
|
2010-08-26 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
EP2614080A1
(en)
|
2010-09-10 |
2013-07-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
EA201370076A1
(ru)
|
2010-09-22 |
2013-08-30 |
Амген Инк. |
Иммуноглобулины-переносчики и их применение
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN106563128B
(zh)
|
2010-10-22 |
2020-05-22 |
西雅图遗传学公司 |
以奥里斯他汀为主的抗体药物结合物和结合mTOR的抑制剂在制备治疗癌症药物中的用途
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
MX357166B
(es)
|
2010-11-24 |
2018-06-28 |
Lexicon Pharmaceuticals Inc |
Anticuerpos que se unen a notum pectinacetilesterasa.
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
WO2012121775A2
(en)
|
2010-12-21 |
2012-09-13 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
KR101941514B1
(ko)
|
2010-12-22 |
2019-01-23 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
개선된 반감기를 가지는 변형된 항체
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
KR20140009311A
(ko)
|
2011-01-18 |
2014-01-22 |
암젠 인크 |
Nav1.7 넉아웃 마우스 및 이의 용도
|
CA2824885A1
(en)
|
2011-01-19 |
2012-07-26 |
Bayer Intellectual Property Gmbh |
Binding proteins to inhibitors of coagulation factors
|
US9315566B2
(en)
|
2011-01-24 |
2016-04-19 |
National University Of Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
AU2012212066A1
(en)
|
2011-02-03 |
2013-08-15 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
ES2770424T3
(es)
|
2011-02-25 |
2020-07-01 |
Regeneron Pharma |
Ratones ADAM6
|
BR112013021725A2
(pt)
|
2011-02-28 |
2016-11-01 |
Genentech Inc |
marcadores biológicos e métodos para prever resposta aos antagonistas de células b
|
JP2014509588A
(ja)
|
2011-03-01 |
2014-04-21 |
アムジエン・インコーポレーテツド |
二特異性結合剤
|
US20130344074A1
(en)
|
2011-03-16 |
2013-12-26 |
Sanofi |
Uses of a dual v region antibody-like protein
|
JP5881085B2
(ja)
|
2011-03-18 |
2016-03-09 |
国立大学法人 鹿児島大学 |
膵臓癌の治療用及び診断用の組成物
|
JP6130350B2
(ja)
|
2011-03-30 |
2017-05-17 |
アブリンクス エン.ヴェー. |
TNFαに対する単一ドメイン抗体で免疫障害を処置する方法
|
CN103619881B
(zh)
|
2011-04-07 |
2017-07-28 |
安姆根有限公司 |
新的egfr结合蛋白
|
EP2696898A4
(en)
|
2011-04-07 |
2014-10-01 |
Univ Emory |
COMPOSITIONS COMPRISING SACCHARIDE BINDING FRACTIONS AND METHODS FOR TARGETED THERAPY
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
WO2012158989A2
(en)
|
2011-05-19 |
2012-11-22 |
The Regents Of The University Of Michigan |
Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
|
MX347818B
(es)
|
2011-05-21 |
2017-05-15 |
Macrogenics Inc |
Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
|
ES2704038T3
(es)
|
2011-05-24 |
2019-03-13 |
Zyngenia Inc |
Complejos multiespecíficos multivalentes y monovalentes y sus usos
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
EP2714094B1
(en)
|
2011-06-02 |
2016-02-24 |
The University of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles
|
CA2837527C
(en)
|
2011-06-02 |
2019-05-28 |
Dyax Corp. |
Fc receptor binding proteins
|
SI2714735T1
(sl)
|
2011-06-03 |
2021-12-31 |
Xoma Technology Ltd. |
Protitelesa, specifična za TGF-beta
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2012170071A1
(en)
|
2011-06-06 |
2012-12-13 |
Elan Pharmaceuticas, Inc |
Mcam antagonists and methods of treatment
|
EP2717911A1
(en)
|
2011-06-06 |
2014-04-16 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
ES2693647T3
(es)
|
2011-06-06 |
2018-12-13 |
Novo Nordisk A/S |
Anticuerpos terapéuticos
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
MX349886B
(es)
|
2011-06-10 |
2017-08-17 |
Medimmune Llc |
Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
|
US20140227265A1
(en)
|
2011-06-17 |
2014-08-14 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
KR20140061403A
(ko)
|
2011-07-13 |
2014-05-21 |
애브비 인코포레이티드 |
항―il―13 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
MY193562A
(en)
|
2011-08-01 |
2022-10-19 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
SG10201606158TA
(en)
|
2011-08-05 |
2016-09-29 |
Regeneron Pharma |
Humanized universal light chain mice
|
AU2012296613B2
(en)
|
2011-08-15 |
2016-05-12 |
Amplimmune, Inc. |
Anti-B7-H4 antibodies and their uses
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
AU2012306341B2
(en)
|
2011-09-09 |
2017-08-31 |
Cambridge Enterprise Limited |
Anti-Siglec-15 antibodies and uses thereof
|
CA2848061C
(en)
|
2011-09-09 |
2019-10-22 |
Amgen Inc. |
Use of human papillomavirus status in establishing use of an agent that binds egfr in the treatment of cancer
|
JP5813880B2
(ja)
|
2011-09-19 |
2015-11-17 |
カイマブ・リミテッド |
ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
|
EP4241785A3
(en)
|
2011-09-20 |
2023-09-27 |
Icahn School of Medicine at Mount Sinai |
Influenza virus vaccines and uses thereof
|
CN103827145A
(zh)
|
2011-09-21 |
2014-05-28 |
富士瑞必欧株式会社 |
相对于亲和性复合物的抗体
|
JP6251678B2
(ja)
|
2011-09-22 |
2017-12-20 |
アムジエン・インコーポレーテツド |
Cd27l抗原結合タンパク質
|
JP2014533929A
(ja)
|
2011-09-23 |
2014-12-18 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
5t4およびcd3に対する二重特異的結合性分子
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
KR102017070B1
(ko)
|
2011-09-30 |
2019-09-02 |
다나-파버 캔서 인스티튜트 인크. |
치료 펩티드
|
MX2014004074A
(es)
|
2011-10-05 |
2014-06-05 |
Genentech Inc |
Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
|
PT2627773T
(pt)
|
2011-10-17 |
2017-09-29 |
Regeneron Pharma |
Ratinhos de cadeia pesada de imunoglobulina restrita
|
WO2013063095A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
IN2014CN03936A
(pt)
|
2011-10-24 |
2015-09-04 |
Abbvie Inc |
|
RS56330B1
(sr)
|
2011-10-28 |
2017-12-29 |
Regeneron Pharma |
Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
|
CA3074400A1
(en)
|
2011-10-28 |
2013-05-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
KR102542272B1
(ko)
|
2011-10-28 |
2023-06-13 |
리제너론 파아마슈티컬스, 인크. |
유전자 변형된 t 세포 수용체 마우스
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
EP3091029B1
(en)
|
2011-10-31 |
2022-12-28 |
F. Hoffmann-La Roche AG |
Anti-il13 antibody formulations
|
US9220774B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of treating cancer by administering anti-GPR49 antibodies
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
EP2773651B1
(en)
|
2011-11-03 |
2020-12-23 |
The Trustees of the University of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
US20140323549A1
(en)
|
2011-11-08 |
2014-10-30 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
MX2014005570A
(es)
|
2011-11-08 |
2014-05-30 |
Pfizer |
El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
CA2855746A1
(en)
|
2011-11-16 |
2013-05-23 |
John Stephen HILL |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
AU2012344260B2
(en)
|
2011-11-28 |
2017-09-07 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP2788384B1
(en)
|
2011-12-08 |
2017-08-09 |
Amgen Inc. |
Agonistic human lcat antigen binding proteins and their use in therapy
|
US10117932B2
(en)
|
2011-12-08 |
2018-11-06 |
Biotest Ag |
Uses of immunoconjugates targeting CD138
|
WO2013090635A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
WO2013090633A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CN104144946A
(zh)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
治疗痤疮的方法
|
BR112014015238B1
(pt)
|
2011-12-20 |
2022-11-16 |
Regeneron Pharmaceuticals, Inc |
Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
CA2861610A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
BR112014017320A2
(pt)
|
2012-01-13 |
2018-05-29 |
Genentech Inc |
método para determinar se um paciente é propenso a responder ao tratamento com um antagonista de vegf, método para otimizar a eficácia terapêutica de um antagonista de vegf, método para selecionar uma terapia, método para identificar um biomarcador e método para diagnosticar um distúrbio angiogênico
|
WO2013107290A1
(en)
|
2012-01-20 |
2013-07-25 |
The Government of the Hong Kong Special Administrative Region of the People's Republic of China |
A novel paramyxovirus and uses thereof
|
NZ625403A
(en)
|
2012-01-27 |
2016-03-31 |
Abbvie Inc |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
MX2014009043A
(es)
|
2012-01-31 |
2014-10-14 |
Genentech Inc |
Anticuerpos anti-ige y sus metodos de uso.
|
EA034778B1
(ru)
|
2012-02-06 |
2020-03-19 |
Инхибркс, Инк. |
Антитела к cd47 и способы их применения
|
GB201202268D0
(en)
|
2012-02-09 |
2012-03-28 |
Medical Res Council |
Intracellular immunity
|
ES2725569T3
(es)
|
2012-02-10 |
2019-09-24 |
Seattle Genetics Inc |
Diagnóstico y tratamiento de cánceres que expresan CD30
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
SI2814842T1
(sl)
|
2012-02-15 |
2018-10-30 |
Novo Nordisk A/S |
Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
|
EP3196214B1
(en)
|
2012-02-15 |
2019-07-31 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
CA2864539C
(en)
|
2012-02-16 |
2022-06-07 |
Santarus, Inc. |
Antibody formulations
|
CA2864702A1
(en)
|
2012-02-22 |
2013-08-29 |
Amgen Inc. |
Autologous mammalian models derived from induced pluripotent stem cells and related methods
|
WO2013128027A1
(en)
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
WO2013148232A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
|
EP2831115A1
(en)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to her3 inhibitors
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
RU2666627C2
(ru)
|
2012-03-30 |
2018-09-11 |
Дженентек, Инк. |
Способы диагностики и композиции для лечения рака
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US9534059B2
(en)
|
2012-04-13 |
2017-01-03 |
Children's Medical Center Corporation |
TIKI inhibitors
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
HUE039118T2
(hu)
|
2012-04-27 |
2018-12-28 |
Novo Nordisk As |
Humán cd30 ligandum antigén kötõ proteinek
|
WO2013166043A1
(en)
|
2012-05-02 |
2013-11-07 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
EP2844291B1
(en)
|
2012-05-03 |
2019-02-13 |
Fibrogen, Inc. |
Methods for treating idiopathic pulmonary fibrosis
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
EP2847219A1
(en)
|
2012-05-07 |
2015-03-18 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
WO2013173364A2
(en)
|
2012-05-14 |
2013-11-21 |
Biogen Idec Ma Inc. |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
BR112014028306A2
(pt)
|
2012-05-15 |
2018-04-17 |
Morphotek, Inc. |
métodos para tratamento de câncer gástrico.
|
WO2013172967A1
(en)
|
2012-05-17 |
2013-11-21 |
Extend Biosciences, Inc |
Carriers for improved drug delivery
|
US9944707B2
(en)
|
2012-05-17 |
2018-04-17 |
Sorrento Therapeutics, Inc. |
Antibodies that bind epidermal growth factor receptor (EGFR)
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
WO2013181452A1
(en)
|
2012-05-31 |
2013-12-05 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
JP6629069B2
(ja)
|
2012-06-06 |
2020-01-15 |
ゾエティス・エルエルシー |
イヌ化抗ngf抗体およびその方法
|
PL3597037T3
(pl)
*
|
2012-06-12 |
2021-10-25 |
Regeneron Pharmaceuticals, Inc. |
Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny
|
KR20150037857A
(ko)
|
2012-06-22 |
2015-04-08 |
싸이톰스 테라퓨틱스, 인크. |
항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법
|
JP6103832B2
(ja)
|
2012-06-25 |
2017-03-29 |
Hoya株式会社 |
Egfr結合性ペプチド
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
US20150218238A1
(en)
|
2012-06-29 |
2015-08-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Treating diseases by modulating a specific isoform of mkl1
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
EP2869818A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
WO2014011988A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
AU2013302441B2
(en)
|
2012-08-17 |
2018-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for detecting complement activation
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
CA2883168A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
HUE049693T2
(hu)
|
2012-08-31 |
2020-10-28 |
Immunogen Inc |
Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
TWI595007B
(zh)
|
2012-09-10 |
2017-08-11 |
Neotope Biosciences Ltd |
抗mcam抗體及相關使用方法
|
NO2760138T3
(pt)
|
2012-10-01 |
2018-08-04 |
|
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
JP6348115B2
(ja)
|
2012-10-26 |
2018-06-27 |
ザ ユニバーシティー オブ クイーンズランド |
がん療法のためのエンドサイトーシス阻害剤および抗体の使用
|
TW202210507A
(zh)
|
2012-11-01 |
2022-03-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
EA034757B1
(ru)
|
2012-12-10 |
2020-03-17 |
Байоджен Ма Инк. |
Антитела против антигена 2 дендритных клеток крови и их применение
|
SG11201504676VA
(en)
*
|
2012-12-14 |
2015-07-30 |
Omt Inc |
Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
|
AU2013362935B2
(en)
|
2012-12-18 |
2018-10-04 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccines and uses thereof
|
WO2014100439A2
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
BR112015014621A2
(pt)
|
2012-12-21 |
2017-10-03 |
Amplimmune Inc |
Anticorpos anti-h7cr
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
ES2944477T3
(es)
|
2013-02-06 |
2023-06-21 |
Inhibrx Inc |
Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
EP3351095A1
(en)
|
2013-02-20 |
2018-07-25 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
DK2958938T3
(da)
|
2013-02-20 |
2019-07-15 |
Regeneron Pharma |
Mus, der eksprimerer humaniserede T-celle-co-receptorer
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
US10154658B2
(en)
|
2013-02-22 |
2018-12-18 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
RU2015140573A
(ru)
|
2013-02-25 |
2017-03-30 |
Дженентек, Инк. |
Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
|
EP3888671A3
(en)
|
2013-03-11 |
2022-01-05 |
Amgen Inc. |
Protein formulations
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
RU2723937C2
(ru)
|
2013-03-13 |
2020-06-18 |
Санофи |
Композиции, включающие антитела к cd38 и карфилзомиб
|
RU2707550C2
(ru)
|
2013-03-13 |
2019-11-27 |
Дженентек, Инк. |
Составы со сниженным окислением
|
SG11201507475UA
(en)
|
2013-03-13 |
2015-10-29 |
Genentech Inc |
Antibody formulations
|
MX369671B
(es)
|
2013-03-13 |
2019-11-15 |
Genentech Inc |
Formulaciones con oxidacion reducida.
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
EP2968468B1
(en)
|
2013-03-13 |
2021-07-14 |
Buzzard Pharmaceuticals AB |
Chimeric cytokine formulations for ocular delivery
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
WO2014153056A2
(en)
|
2013-03-14 |
2014-09-25 |
Parkash Gill |
Cancer treatment using antibodies that bing cell surface grp78
|
EP3841876A1
(en)
|
2013-03-14 |
2021-06-30 |
Erasmus University Medical Center Rotterdam |
Transgenic mouse for antibody production
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
EP2970451A1
(en)
|
2013-03-14 |
2016-01-20 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
BR112015023239A8
(pt)
|
2013-03-14 |
2018-04-17 |
Abbott Lab |
ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014143342A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
|
CA2906417C
(en)
|
2013-03-14 |
2022-06-21 |
Robert Ziemann |
Hcv core lipid binding domain monoclonal antibodies
|
US9908930B2
(en)
|
2013-03-14 |
2018-03-06 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
ES2699599T3
(es)
|
2013-03-15 |
2019-02-11 |
Abbvie Biotherapeutics Inc |
Variantes de Fc
|
NZ712300A
(en)
|
2013-03-15 |
2020-07-31 |
Sutter West Bay Hospitals |
Falz for use as a target for therapies to treat cancer
|
WO2014144632A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Human pac1 antibodies
|
US9062108B2
(en)
|
2013-03-15 |
2015-06-23 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 and/or IL-17
|
CN105392801A
(zh)
|
2013-03-15 |
2016-03-09 |
比奥根Ma公司 |
使用抗αvβ5抗体治疗和预防急性肾损伤
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
WO2014140358A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Single chain binding molecules comprising n-terminal abp
|
EP4079760A3
(en)
|
2013-03-15 |
2023-01-25 |
Sanofi Pasteur Inc. |
Antibodies against clostridium difficile toxins and methods of using the same
|
RU2015144026A
(ru)
|
2013-03-15 |
2017-04-20 |
Эббви Байотекнолоджи Лтд. |
Антитела против cd25 и их применения
|
RU2015144020A
(ru)
|
2013-03-15 |
2017-04-21 |
Дженентек, Инк. |
Среды для культивирования клеток и способы получения антител
|
CA2904527A1
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Biotechnology Ltd. |
Anti-cd25 antibodies and their uses
|
EP2970483A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Inc. |
Methods and compositions relating to anti-ccr7 antigen binding proteins
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
CA2903576C
(en)
|
2013-03-15 |
2021-06-08 |
Nai-Kong V. Cheung |
High affinity anti-gd2 antibodies
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
CN105142668B
(zh)
|
2013-03-15 |
2018-04-27 |
达纳-法伯癌症研究院公司 |
治疗性肽
|
KR20210037745A
(ko)
|
2013-03-15 |
2021-04-06 |
제넨테크, 인크. |
항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
EP2983710B1
(en)
|
2013-04-09 |
2019-07-31 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗il-4/抗il-13之雙特異性抗體調配物
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
PL2981822T3
(pl)
|
2013-05-06 |
2021-07-12 |
Scholar Rock, Inc. |
Kompozycje i sposoby modulacji czynnika wzrostu
|
WO2014182972A2
(en)
|
2013-05-10 |
2014-11-13 |
The Regents Of The University Of California |
Diagnostic and monitoring system for huntington's disease
|
WO2014190356A2
(en)
|
2013-05-24 |
2014-11-27 |
Amplimmune, Inc. |
Anti-b7-h5 antibodies and their uses
|
PT3004167T
(pt)
|
2013-05-30 |
2018-11-13 |
Kiniksa Pharmaceuticals Ltd |
Proteínas de ligação ao antigénio do recetor da oncostatina m
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014197866A1
(en)
|
2013-06-06 |
2014-12-11 |
Igenica Biotherapeutics, Inc. |
Modified antibodies and related compounds, compositions, and methods of use
|
ES2753419T3
(es)
|
2013-06-07 |
2020-04-08 |
Univ Duke |
Inhibidores del factor H del complemento
|
JP2016521744A
(ja)
|
2013-06-13 |
2016-07-25 |
ファスト フォワード ファーマスーティカルズ ベー.フェー. |
追加化合物が胆汁酸、胆汁酸誘導体、tgr5受容体作動物質、fxr作動物質またはそれらの組合せである、慢性炎症の治療および消化器癌または線維症の予防のためのcd40シグナル伝達阻害物質および追加化合物
|
US9499628B2
(en)
|
2013-06-14 |
2016-11-22 |
Children's Hospital Medical Center |
Method of boosting the immune response in neonates
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
AU2013396206B2
(en)
|
2013-06-28 |
2019-11-14 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
NZ715455A
(en)
|
2013-07-09 |
2021-12-24 |
Annexon Inc |
Anti-complement factor c1q antibodies and uses thereof
|
BR112016000853A2
(pt)
|
2013-07-16 |
2017-12-12 |
Genentech Inc |
métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN105814074B
(zh)
|
2013-07-18 |
2020-04-21 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
CN105531291A
(zh)
|
2013-08-07 |
2016-04-27 |
阿斯图特医药公司 |
用于生物样品中的具有提高的性能的timp2测定
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
CA2921398C
(en)
|
2013-08-14 |
2021-12-14 |
The Governing Council Of The University Of Toronto |
Antibodies for inhibiting frizzled receptors and pharmaceutical compositions containing antibodies for inhibiting frizzled receptors
|
WO2015026846A1
(en)
|
2013-08-19 |
2015-02-26 |
Biogen Idec Ma Inc. |
Control of protein glycosylation by culture medium supplementation and cell culture process parameters
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
EA033817B1
(ru)
|
2013-09-27 |
2019-11-28 |
Genentech Inc |
Композиции, содержащие антитело к pdl1
|
WO2015049517A2
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
JP6534654B2
(ja)
|
2013-10-10 |
2019-06-26 |
ベス イスラエル デアコネス メディカル センター インコーポレイティッド |
Tm4sf1結合性タンパク質およびそれを使用する方法
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
EP3063317B1
(en)
|
2013-10-28 |
2020-06-03 |
DOTS Technology Corp. |
Allergen detection
|
BR112016009403A2
(pt)
|
2013-10-31 |
2017-09-19 |
Sanofi Sa |
Anticorpos anti-cd38 específicos para tratamento de cânceres humanos
|
EP3066221A4
(en)
|
2013-11-06 |
2017-09-20 |
Astute Medical, Inc. |
Assays for igfbp7 having improved performance in biological samples
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
MX371187B
(es)
|
2013-12-06 |
2020-01-22 |
Dana Farber Cancer Inst Inc |
Péptidos terapéuticos.
|
KR20160097294A
(ko)
|
2013-12-09 |
2016-08-17 |
뉴욕 유니버시티 |
항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
|
US9944694B2
(en)
|
2013-12-13 |
2018-04-17 |
Rijksuniversiteit Groningen |
Antibodies against Staphylococcus aureus and uses therof
|
AU2014364593A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
PT3083686T
(pt)
|
2013-12-17 |
2019-12-18 |
Hoffmann La Roche |
Métodos de tratamento de cancros com antagonistas da ligação ao eixo pd-1 e taxanos
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
EP3083964B1
(en)
|
2013-12-19 |
2022-01-26 |
Novartis AG |
Human mesothelin chimeric antigen receptors and uses thereof
|
JP2017500017A
(ja)
|
2013-12-20 |
2017-01-05 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
|
CA3204788A1
(en)
|
2013-12-20 |
2015-06-25 |
Genentech, Inc. |
Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
|
SI3712174T1
(sl)
|
2013-12-24 |
2022-06-30 |
Janssen Pharmaceutica Nv |
Protitelesa in delci proti VISTA
|
EP2893939A1
(en)
|
2014-01-10 |
2015-07-15 |
Netris Pharma |
Anti-netrin-1 antibody
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
EP3925973A1
(en)
|
2014-03-14 |
2021-12-22 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
KR102601491B1
(ko)
|
2014-03-21 |
2023-11-13 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
SG11201607015VA
(en)
|
2014-03-21 |
2016-09-29 |
Regeneron Pharma |
V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
|
WO2015148515A1
(en)
|
2014-03-24 |
2015-10-01 |
Biogen Ma Inc. |
Methods for overcoming glutamine deprivation during mammalian cell culture
|
KR102352250B1
(ko)
|
2014-03-25 |
2022-01-17 |
제넨테크, 인크. |
세포 배양 배지에 사용하기 위한 폴록사머를 제조하는 방법
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
KR102352573B1
(ko)
|
2014-04-04 |
2022-01-18 |
바이오노믹스 인코포레이티드 |
Lgr5에 결합하는 인간화된 항체들
|
EP3804745A1
(en)
|
2014-04-25 |
2021-04-14 |
The Brigham and Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
WO2015175874A2
(en)
|
2014-05-16 |
2015-11-19 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
US20170198054A1
(en)
|
2014-05-21 |
2017-07-13 |
Dana-Farber Cancer Institute |
Methods for treating cancer with anti bip or anti mica antibodies
|
EP3149036A4
(en)
|
2014-05-27 |
2017-12-27 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
EP4116329A1
(en)
|
2014-05-27 |
2023-01-11 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
TWI717319B
(zh)
|
2014-05-27 |
2021-02-01 |
中央研究院 |
得自類桿菌屬之岩藻糖苷酶及其用途
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
MA47849A
(fr)
|
2014-05-28 |
2020-01-29 |
Agenus Inc |
Anticorps anti-gitr et leurs procédés d'utilisation
|
EP3154579A1
(en)
|
2014-06-13 |
2017-04-19 |
Friedrich Miescher Institute for Biomedical Research |
New treatment against influenza virus
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
EP3164129A1
(en)
|
2014-07-01 |
2017-05-10 |
Friedrich Miescher Institute for Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
CN106686977B
(zh)
|
2014-07-09 |
2022-03-25 |
豪夫迈·罗氏有限公司 |
Ph调整以改善细胞库的解冻复苏
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
JP6673896B2
(ja)
|
2014-07-15 |
2020-03-25 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びmek阻害剤を使用した癌を処置するための組成物
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
JP6738316B2
(ja)
|
2014-07-17 |
2020-08-12 |
ノヴォ ノルディスク アクティーゼルスカブ |
粘度を低下させるためのtrem−1抗体の部位特異的変異誘発
|
US20170275373A1
(en)
|
2014-07-31 |
2017-09-28 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
CA2956471A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
EP3177322A4
(en)
|
2014-08-08 |
2018-07-18 |
Alector LLC |
Anti-trem2 antibodies and methods of use thereof
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
US10961298B2
(en)
|
2014-08-21 |
2021-03-30 |
The Government Of The United States, Represented By The Secretary Of The Army |
Monoclonal antibodies for treatment of microbial infections
|
RU2741470C9
(ru)
|
2014-09-02 |
2021-04-27 |
Иммьюноджен, Инк. |
Способы составления композиций конъюгата антитело-лекарственное средство
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
ES2949173T3
(es)
|
2014-09-15 |
2023-09-26 |
Hoffmann La Roche |
Formulaciones de anticuerpo
|
WO2016044224A1
(en)
|
2014-09-15 |
2016-03-24 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
WO2016044588A1
(en)
|
2014-09-19 |
2016-03-24 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
RU2017113134A
(ru)
|
2014-09-19 |
2018-10-19 |
Регенерон Фармасьютикалз, Инк. |
Химерные антигенные рецепторы
|
EP3197557A1
(en)
|
2014-09-24 |
2017-08-02 |
Friedrich Miescher Institute for Biomedical Research |
Lats and breast cancer
|
US10202616B2
(en)
|
2014-10-15 |
2019-02-12 |
Amgen Inc. |
Promoter and regulatory elements for improved expression of heterologous genes in host cells
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
EP3220961B1
(en)
|
2014-10-22 |
2023-07-05 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
EP4219725A3
(en)
|
2014-10-31 |
2023-08-30 |
The Trustees of the University of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
EP3212668B1
(en)
|
2014-10-31 |
2020-10-14 |
AbbVie Biotherapeutics Inc. |
Anti-cs1 antibodies and antibody drug conjugates
|
ES2910227T3
(es)
|
2014-10-31 |
2022-05-12 |
Univ Pennsylvania |
Composición y métodos para la estimulación y expansión de células T
|
JP6875276B2
(ja)
|
2014-11-05 |
2021-05-19 |
ジェネンテック, インコーポレイテッド |
細菌における2鎖タンパク質の生成方法
|
AU2015342964B2
(en)
|
2014-11-05 |
2021-06-24 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
BR112017009297B1
(pt)
|
2014-11-05 |
2024-02-15 |
Annexon, Inc |
Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
|
JP2017534633A
(ja)
|
2014-11-06 |
2017-11-24 |
ジェネンテック, インコーポレイテッド |
Ox40結合アゴニスト及びtigit阻害剤を含む組み合わせ療法
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US20170306046A1
(en)
|
2014-11-12 |
2017-10-26 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
EP3221360A1
(en)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
SG11201704058TA
(en)
|
2014-11-18 |
2017-06-29 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
EP3221340A1
(en)
|
2014-11-19 |
2017-09-27 |
Koninklijke Philips N.V. |
Diagnostic method employing hnl
|
US10517898B2
(en)
|
2014-11-20 |
2019-12-31 |
The Regents Of The University Of California |
Compositions and methods related to hematologic recovery
|
EP3220900B1
(en)
|
2014-11-21 |
2020-09-23 |
University of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
WO2016090300A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
CA2970155A1
(en)
|
2014-12-09 |
2016-06-16 |
Abbvie Inc. |
Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
|
CN107249643A
(zh)
|
2014-12-09 |
2017-10-13 |
艾伯维公司 |
具有细胞渗透性的bcl‑xl抑制剂的抗体药物缀合物
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
KR20170087500A
(ko)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
ES2870983T3
(es)
|
2014-12-19 |
2021-10-28 |
Univ Nantes |
Anticuerpos anti-IL-34
|
JP7211703B2
(ja)
|
2014-12-22 |
2023-01-24 |
ザ ロックフェラー ユニバーシティー |
抗mertkアゴニスト抗体及びその使用
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
CN107530423B
(zh)
|
2015-01-14 |
2022-04-05 |
布里格姆及妇女医院股份有限公司 |
用抗lap单克隆抗体治疗癌症
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
CA2974699A1
(en)
|
2015-01-23 |
2016-07-28 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
TWI710571B
(zh)
|
2015-01-24 |
2020-11-21 |
中央研究院 |
腫瘤標記及其使用方法
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
CA2973886A1
(en)
|
2015-01-30 |
2016-08-04 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP7170394B2
(ja)
|
2015-01-31 |
2022-11-14 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
治療用分子のt細胞送達のための組成物および方法
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US10988534B2
(en)
|
2015-02-09 |
2021-04-27 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
|
WO2016137985A1
(en)
|
2015-02-26 |
2016-09-01 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
EP3265491A1
(en)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
FI3265123T3
(fi)
|
2015-03-03 |
2023-01-31 |
|
Vasta-aineita, käyttöjä & menetelmiä
|
EP3265483B1
(en)
|
2015-03-06 |
2019-12-11 |
CSL Behring Lengnau AG |
Modified von willebrand factor having improved half-life
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
CN107438622A
(zh)
|
2015-03-19 |
2017-12-05 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
US20180087087A1
(en)
|
2015-03-25 |
2018-03-29 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
|
EP3274724A1
(en)
|
2015-03-25 |
2018-01-31 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
WO2016161446A1
(en)
*
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
EP3277716B1
(en)
|
2015-04-03 |
2020-06-24 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
EP3280257B1
(en)
|
2015-04-06 |
2023-06-07 |
Regeneron Pharmaceuticals, Inc. |
Humanized t cell mediated immune responses in non-human animals
|
PL3280441T3
(pl)
|
2015-04-07 |
2022-02-21 |
Alector Llc |
Przeciwciała przeciwko sortilinie i sposoby ich stosowania
|
WO2016164608A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
SG10201909308XA
(en)
|
2015-04-17 |
2019-11-28 |
Amgen Res Munich Gmbh |
Bispecific antibody constructs for cdh3 and cd3
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
EP3291839A1
(en)
|
2015-05-05 |
2018-03-14 |
The University of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
US10259882B2
(en)
|
2015-05-07 |
2019-04-16 |
Agenus Inc. |
Anti-OX40 antibodies
|
WO2016183104A1
(en)
|
2015-05-11 |
2016-11-17 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
MX2017014381A
(es)
|
2015-05-12 |
2018-03-02 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
CA3025145A1
(en)
|
2015-05-22 |
2016-12-01 |
Translational Drug Development Llc |
Benzamide and active compound compositions and methods of use
|
PL3303632T5
(pl)
|
2015-05-29 |
2023-07-03 |
F. Hoffmann-La Roche Ag |
Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
|
EP3303395B1
(en)
|
2015-05-29 |
2019-12-11 |
AbbVie Inc. |
Anti-cd40 antibodies and uses thereof
|
PL3303394T3
(pl)
|
2015-05-29 |
2020-11-16 |
Agenus Inc. |
Przeciwciała anty-ctla-4 i sposoby ich zastosowania
|
CA3026154A1
(en)
|
2015-06-03 |
2016-12-08 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
SG10201912085WA
(en)
|
2015-06-12 |
2020-02-27 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
EP3307779A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
MX2017016324A
(es)
|
2015-06-16 |
2018-03-02 |
Merck Patent Gmbh |
Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
CA2990360C
(en)
|
2015-06-24 |
2024-02-13 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
JP2018520153A
(ja)
|
2015-06-29 |
2018-07-26 |
ジェネンテック, インコーポレイテッド |
臓器移植における使用のためのii型抗cd20抗体
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
AU2016304588A1
(en)
|
2015-08-06 |
2018-02-15 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
EP3337822A1
(en)
|
2015-08-19 |
2018-06-27 |
Rutgers, The State University of New Jersey |
Novel methods of generating antibodies
|
WO2017029346A1
(en)
|
2015-08-20 |
2017-02-23 |
F. Hoffmann-La Roche Ag |
Particle-based immunoassay using a pegylated analyte-specific binding agent
|
WO2017035252A1
(en)
|
2015-08-24 |
2017-03-02 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
CN108137702B
(zh)
|
2015-08-28 |
2023-01-06 |
艾利妥 |
抗siglec-7抗体及其使用方法
|
IL307276A
(en)
|
2015-08-28 |
2023-11-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
BR112018003186A2
(pt)
|
2015-09-01 |
2018-09-25 |
Agenus Inc. |
anticorpos anti-pd-1 e seus métodos de uso
|
AR105910A1
(es)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
Matrices de glicano y método de uso
|
MA42821A
(fr)
|
2015-09-15 |
2018-07-25 |
Amgen Inc |
Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
|
JP2018535655A
(ja)
|
2015-09-29 |
2018-12-06 |
アムジエン・インコーポレーテツド |
Asgr阻害剤
|
WO2017058780A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
AU2016334051B2
(en)
|
2015-10-06 |
2023-10-26 |
Alector Llc |
Anti-TREM2 antibodies and methods of use thereof
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
CN116003596A
(zh)
|
2015-10-29 |
2023-04-25 |
艾利妥 |
抗siglec-9抗体及其使用方法
|
AR106543A1
(es)
|
2015-11-02 |
2018-01-24 |
Netris Pharma |
Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
|
US11235063B2
(en)
|
2015-11-03 |
2022-02-01 |
Merck Patent Gmbh |
Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
|
CN116217729A
(zh)
|
2015-11-12 |
2023-06-06 |
思进公司 |
聚糖相互作用化合物及使用方法
|
US20170189548A1
(en)
|
2015-11-25 |
2017-07-06 |
Immunogen, Inc. |
Pharmaceutical formulations and methods of use thereof
|
EP3383910A1
(en)
|
2015-11-30 |
2018-10-10 |
AbbVie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
JP2019500327A
(ja)
|
2015-11-30 |
2019-01-10 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
ES2861449T3
(es)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
|
KR20180100122A
(ko)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
WO2017095939A1
(en)
|
2015-12-03 |
2017-06-08 |
Trianni, Inc. |
Enhanced immunoglobulin diversity
|
EP3390447A1
(en)
|
2015-12-15 |
2018-10-24 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
SG11201805255TA
(en)
|
2015-12-23 |
2018-07-30 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
EP3184544A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein v inhibitors for use as coagulants
|
WO2017117304A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
AU2016380988B2
(en)
|
2015-12-30 |
2022-07-21 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
SG11201805141QA
(en)
|
2015-12-31 |
2018-07-30 |
Progastrine Et Cancers S A R L |
Compositions and methods for detecting and treating gastric cancer
|
AU2017204683B2
(en)
|
2015-12-31 |
2023-03-16 |
Syncerus S.À R.L. |
Compositions and methods for assessing the risk of cancer occurrence
|
US11789021B2
(en)
|
2015-12-31 |
2023-10-17 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating esophageal cancer
|
SG11201805605TA
(en)
|
2015-12-31 |
2018-07-30 |
Progastrine Et Cancers S A R L |
Compositions and methods for detecting and treating ovarian cancer
|
IL259588B2
(en)
|
2016-01-08 |
2023-09-01 |
Hoffmann La Roche |
Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3
|
US11103589B2
(en)
|
2016-01-08 |
2021-08-31 |
Apg Therapeutics, Inc. |
Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
BR112018015715A2
(pt)
|
2016-02-03 |
2019-02-05 |
Amgen Inc |
construtos de anticorpo de engate de célula t biespecífica bcma e cd3
|
EP3411404B1
(en)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma and cd3 bispecific t cell engaging antibody constructs
|
JP6929877B2
(ja)
|
2016-02-04 |
2021-09-01 |
トリアニ・インコーポレイテッドTrianni, Inc. |
免疫グロブリン産生の増強
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
JP2019509993A
(ja)
|
2016-02-12 |
2019-04-11 |
ヤンセン ファーマシューティカ エヌブイ |
抗vista(b7h5)抗体
|
WO2017151502A1
(en)
|
2016-02-29 |
2017-09-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP7023853B2
(ja)
|
2016-03-04 |
2022-02-22 |
アレクトル エルエルシー |
抗trem1抗体及びその使用方法
|
CN109071669A
(zh)
|
2016-03-07 |
2018-12-21 |
查尔斯顿制药有限责任公司 |
抗核仁素抗体
|
CA3016170A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
AU2017234163B2
(en)
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
BR112018067923A2
(pt)
|
2016-03-15 |
2019-02-05 |
Chugai Pharmaceutical Co Ltd |
métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
|
EP3430044A1
(en)
|
2016-03-17 |
2019-01-23 |
Numab Innovation AG |
Anti-tnf alpha -antibodies and functional fragments thereof
|
PT3219726T
(pt)
|
2016-03-17 |
2020-12-15 |
Tillotts Pharma Ag |
Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
|
LT3219727T
(lt)
|
2016-03-17 |
2021-02-10 |
Tillotts Pharma Ag |
Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
|
EA039201B1
(ru)
|
2016-03-17 |
2021-12-16 |
Нумаб Инновейшн Аг |
Антитела к фно и их функциональные фрагменты
|
JP7049311B2
(ja)
|
2016-03-17 |
2022-04-06 |
ヌマブ イノヴェイション アーゲー |
抗TNFα抗体およびそれらの機能的断片
|
CN108697799A
(zh)
|
2016-03-22 |
2018-10-23 |
生态学有限公司 |
抗lgr5单克隆抗体的施用
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
TWI780045B
(zh)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
抗體、醫藥組合物及方法
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
AU2017241776A1
(en)
|
2016-03-29 |
2018-10-11 |
Janssen Biotech, Inc. |
Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
ES2850428T3
(es)
|
2016-04-15 |
2021-08-30 |
Hoffmann La Roche |
Procedimientos de monitorización y tratamiento del cáncer
|
WO2017181079A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
KR20230110820A
(ko)
|
2016-04-22 |
2023-07-25 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
|
JP7181091B2
(ja)
|
2016-05-10 |
2022-11-30 |
ジェネンテック, インコーポレイテッド |
ポリペプチドの組み換え産生中にトリスルフィド結合を減少させる方法
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Hdac抑制劑與pd-l1抑制劑之組合治療
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗muc1類美登素免疫綴合物抗體治療腫瘤的治療方案
|
DK3458102T3
(da)
|
2016-05-17 |
2020-07-27 |
Abbvie Biotherapeutics Inc |
Anti-cmet-antistoflægemiddelkonjugater og fremgangsmåder til anvendelse deraf
|
CN109415441B
(zh)
|
2016-05-24 |
2023-04-07 |
英斯梅德股份有限公司 |
抗体及其制备方法
|
EP3464356A1
(en)
|
2016-05-26 |
2019-04-10 |
Merck Patent GmbH |
Pd-1 / pd-l1 inhibitors for cancer treatment
|
UA123111C2
(uk)
|
2016-05-27 |
2021-02-17 |
Еббві Байотерапьютікс Інк. |
Антитіло до cd40 та його застосування
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
WO2017205745A1
(en)
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Anti-4-1bb antibodies and their uses
|
RU2753585C2
(ru)
|
2016-06-03 |
2021-08-18 |
Регенерон Фармасьютикалз, Инк. |
Животные, не являющиеся человеком, экспрессирующие экзогенную терминальную дезоксинуклеотидилтрансферазу
|
PE20190177A1
(es)
|
2016-06-08 |
2019-02-01 |
Abbvie Inc |
Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco
|
CN113773387A
(zh)
|
2016-06-13 |
2021-12-10 |
天境生物科技(上海)有限公司 |
Pd-l1抗体及其用途
|
WO2017218624A1
(en)
|
2016-06-15 |
2017-12-21 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus hemagglutinin proteins and uses thereof
|
KR20190039937A
(ko)
|
2016-07-08 |
2019-04-16 |
스태튼 바이오테크놀로지 비.브이. |
항-ApoC3 항체 및 이의 사용 방법
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3487867A2
(en)
|
2016-07-22 |
2019-05-29 |
Amgen Inc. |
Methods of purifying fc-containing proteins
|
MA45715A
(fr)
|
2016-07-25 |
2019-05-29 |
Biogen Ma Inc |
Anticorps anti-hspa5 (grp78) et leurs utilisations
|
CA3032049C
(en)
|
2016-07-27 |
2023-11-07 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
JP7148493B2
(ja)
|
2016-08-01 |
2022-10-05 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
副甲状腺ホルモン受容体1(pth1r)抗体およびその使用
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
MX2019001635A
(es)
|
2016-08-12 |
2019-06-10 |
Genentech Inc |
Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
WO2018049083A1
(en)
|
2016-09-07 |
2018-03-15 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
TW201825674A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現雙特異性接合分子的溶瘤病毒
|
PL3512547T3
(pl)
|
2016-09-14 |
2021-03-08 |
Abbvie Biotherapeutics Inc. |
Przeciwciała anty-pd-1
|
WO2018050111A1
(en)
|
2016-09-19 |
2018-03-22 |
I-Mab |
Anti-gm-csf antibodies and uses thereof
|
KR20240035625A
(ko)
|
2016-09-21 |
2024-03-15 |
넥스트큐어 인코포레이티드 |
Siglec-15를 위한 항체 및 이의 사용 방법
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
US10858428B2
(en)
|
2016-09-28 |
2020-12-08 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
BR112019005815A2
(pt)
|
2016-09-29 |
2019-06-25 |
Genentech Inc |
métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama
|
KR20190059305A
(ko)
|
2016-09-30 |
2019-05-30 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
|
EP3519824A1
(en)
|
2016-10-03 |
2019-08-07 |
Abbott Laboratories |
Improved methods of assessing uch-l1 status in patient samples
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
BR112019006504A2
(pt)
|
2016-10-06 |
2019-06-25 |
Merck Patent Gmbh |
regime de dosagem de avelumabe para o tratamento de câncer
|
MA46529A
(fr)
|
2016-10-11 |
2019-08-21 |
Agenus Inc |
Anticorps anti-lag-3 et leurs procédés d'utilisation
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
WO2018081578A1
(en)
|
2016-10-28 |
2018-05-03 |
Astute Medical, Inc. |
Use of antibodies to timp-2 for the improvement of renal function
|
CA3041843A1
(en)
|
2016-11-02 |
2018-05-11 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
CA3042989A1
(en)
|
2016-11-07 |
2018-05-11 |
Junho Chung |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
EP3538549A1
(en)
|
2016-11-10 |
2019-09-18 |
iOmx Therapeutics AG |
Or10h1 antigen binding proteins and uses thereof
|
AU2017356317A1
(en)
|
2016-11-14 |
2019-05-30 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
WO2018093841A1
(en)
|
2016-11-16 |
2018-05-24 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-il-23 specific antibody
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
EP3541414A4
(en)
|
2016-11-21 |
2020-11-11 |
OBI Pharma, Inc. |
CONJUGATE BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES
|
CA3082255A1
(en)
|
2016-11-23 |
2020-06-10 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
JP6992068B2
(ja)
|
2016-12-07 |
2022-02-03 |
アジェナス インコーポレイテッド |
抗ctla-4抗体およびそれらの使用方法
|
BR112019012328A2
(pt)
|
2016-12-15 |
2019-11-19 |
Abbvie Biotherapeutics Inc |
anticorpos anti-ox40 e seus usos
|
EP3562845A2
(en)
|
2016-12-27 |
2019-11-06 |
H. Hoffnabb-La Roche Ag |
Novel biotin-specific monoclonal antibody and use thereof
|
BR112019010915A2
(pt)
|
2016-12-27 |
2019-10-01 |
Hoffmann La Roche |
anticorpo monoclonal, métodos para medir um analito em uma amostra e para produzir um anticorpo, uso de um anticorpo, kit de teste de imunoensaio e imunógeno
|
JP6901561B2
(ja)
|
2016-12-27 |
2021-07-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規のビオチン特異的モノクローナル抗体およびその使用
|
US20190315852A1
(en)
|
2017-01-05 |
2019-10-17 |
Netris Pharma |
Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
MX2019007848A
(es)
|
2017-01-20 |
2019-09-09 |
Tayu Huaxia Biotech Medical Group Co Ltd |
Anticuerpos anti-pd-1 y usos de los mismos.
|
LT3383916T
(lt)
|
2017-01-24 |
2022-06-10 |
I-Mab Biopharma Us Limited |
Antikūnai prieš cd73 ir jų panaudojimo būdai
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
EP3574012A1
(en)
|
2017-01-27 |
2019-12-04 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
JP2020506916A
(ja)
|
2017-01-30 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性乾癬性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
EP3577460B1
(en)
|
2017-02-02 |
2021-01-20 |
Roche Diagnostics GmbH |
Immunoassay using at least two pegylated analyte-specific binding agents
|
KR20190115042A
(ko)
|
2017-02-07 |
2019-10-10 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
WO2018156180A1
(en)
|
2017-02-24 |
2018-08-30 |
Kindred Biosciences, Inc. |
Anti-il31 antibodies for veterinary use
|
MX2019010295A
(es)
|
2017-03-01 |
2019-11-21 |
Genentech Inc |
Métodos de diagnóstico y terapéuticos para el cáncer.
|
EP3589319A4
(en)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
|
TWI808963B
(zh)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
使用人類化抗cxcr5抗體治療狼瘡
|
JP7346300B2
(ja)
|
2017-03-23 |
2023-09-19 |
アボット・ラボラトリーズ |
早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼl1を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
|
RU2765997C2
(ru)
|
2017-03-30 |
2022-02-07 |
Мерк Патент Гмбх |
Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
|
EP3601343B1
(en)
|
2017-03-30 |
2022-05-04 |
ECS-Progastrin SA |
Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
|
US11561225B2
(en)
|
2017-03-30 |
2023-01-24 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for treating lung cancer
|
JP7291398B2
(ja)
|
2017-03-30 |
2023-06-15 |
ザ ユニバーシティー オブ クイーンズランド |
キメラ分子およびその使用
|
EP3606554A4
(en)
|
2017-04-05 |
2020-12-09 |
Astute Medical, Inc. |
ASSAYS FOR TIMP2 WITH IMPROVED EFFICIENCY IN BIOLOGICAL SAMPLES
|
CA3058652A1
(en)
|
2017-04-07 |
2018-10-11 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
JP7344797B2
(ja)
|
2017-04-15 |
2023-09-14 |
アボット・ラボラトリーズ |
早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
|
CN110506056A
(zh)
|
2017-04-21 |
2019-11-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体和其使用方法
|
CN110799529A
(zh)
|
2017-04-22 |
2020-02-14 |
免疫治疗有限公司 |
改良lamp构建物
|
WO2018196782A1
(en)
|
2017-04-27 |
2018-11-01 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
CN110603449A
(zh)
|
2017-04-28 |
2019-12-20 |
雅培实验室 |
用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
|
PL3618863T3
(pl)
|
2017-05-01 |
2023-11-06 |
Agenus Inc. |
Przeciwciała anty- tigit i sposoby ich zastosowania
|
IL297073B2
(en)
|
2017-05-02 |
2023-12-01 |
Immunomic Therapeutics Inc |
LAMP constructs containing cancer antigens
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
AU2018261951A1
(en)
|
2017-05-05 |
2019-10-31 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
US10914729B2
(en)
|
2017-05-22 |
2021-02-09 |
The Trustees Of Princeton University |
Methods for detecting protein binding sequences and tagging nucleic acids
|
CA3063344A1
(en)
|
2017-05-23 |
2018-11-29 |
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) |
Novel cd73 antibody, preparation and uses thereof
|
WO2018218169A1
(en)
|
2017-05-25 |
2018-11-29 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
US10849548B2
(en)
|
2017-05-30 |
2020-12-01 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
KR20200026209A
(ko)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
JP7237853B2
(ja)
|
2017-06-20 |
2023-03-13 |
アムジエン・インコーポレーテツド |
胃抑制ペプチド受容体(gipr)に対する結合タンパク質をglp-1アゴニストと組み合わせて使用する、代謝障害の治療方法又は寛解方法
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
CR20200076A
(es)
|
2017-07-14 |
2020-06-10 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
KR20200093518A
(ko)
|
2017-07-21 |
2020-08-05 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
EP3625250B1
(en)
|
2017-07-21 |
2021-04-14 |
Trianni, Inc. |
Single chain vh and heavy chain antibodies
|
EP3658178A1
(en)
|
2017-07-27 |
2020-06-03 |
Nomocan Pharmaceuticals LLC |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
SI3601358T1
(sl)
|
2017-08-03 |
2023-10-30 |
Alector Llc |
Protitelesa ANTI-TREM2 in načini njihove uporabe
|
HUE058233T2
(hu)
|
2017-08-03 |
2022-07-28 |
Amgen Inc |
Interleukin-21-muteinek és kezelési eljárások
|
CR20190486A
(es)
|
2017-08-03 |
2020-02-10 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
JP2020529986A
(ja)
|
2017-08-04 |
2020-10-15 |
アムジエン・インコーポレーテツド |
Cys−mabのコンジュゲーション方法
|
WO2019036856A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
DYNAMIC BANKS OF LIGHT CHAIN OF HUMAN ANTIBODY
|
US11578426B2
(en)
|
2017-08-21 |
2023-02-14 |
Adagene Inc. |
Dynamic human heavy chain antibody libraries
|
CN111133005A
(zh)
|
2017-09-07 |
2020-05-08 |
奥古斯塔大学研究所公司 |
程序性细胞死亡蛋白1抗体
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
CN111133001B
(zh)
|
2017-09-22 |
2024-02-06 |
豪夫迈·罗氏有限公司 |
用于分析目的的多价单或双特异性重组抗体
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
WO2019083904A1
(en)
|
2017-10-23 |
2019-05-02 |
Chan Zuckerberg Biohub, Inc. |
AFUCOSYLATED IGG FC GLYCANES MEASUREMENT AND METHODS OF TREATMENT THEREOF
|
JP7403164B2
(ja)
|
2017-10-26 |
2023-12-22 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
虚血性再灌流障害を治療するための酸化特異的エピトープの阻害
|
EP3476942B1
(en)
|
2017-10-27 |
2022-01-26 |
Trianni, Inc. |
Long germline dh genes and long hcdr3 antibodies
|
SG11202003980PA
(en)
|
2017-10-31 |
2020-05-28 |
Staten Biotechnology B V |
Anti-apoc3 antibodies and methods of use thereof
|
TW201922294A
(zh)
|
2017-10-31 |
2019-06-16 |
美商伊繆諾金公司 |
抗體-藥物結合物與阿糖胞苷之組合治療
|
JP2021502066A
(ja)
|
2017-11-06 |
2021-01-28 |
ジェネンテック, インコーポレイテッド |
がんの診断及び療法
|
AU2018371271A1
(en)
|
2017-11-27 |
2020-06-11 |
Purdue Pharma L.P. |
Humanized antibodies targeting human tissue factor
|
CA3084687C
(en)
|
2017-12-05 |
2024-01-02 |
Progastrine Et Cancers S.A R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
SG11202003044SA
(en)
*
|
2017-12-05 |
2020-04-29 |
Regeneron Pharma |
Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
|
CA3083783A1
(en)
|
2017-12-06 |
2019-06-13 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
CA3067057A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
JP7379165B2
(ja)
|
2017-12-09 |
2023-11-14 |
アボット・ラボラトリーズ |
Gfapとuch-l1との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
|
US20210163592A1
(en)
|
2017-12-11 |
2021-06-03 |
Amgen Inc |
Continuous manufacturing process for bispecific antibody products
|
DK3710484T3
(da)
|
2017-12-20 |
2023-11-27 |
Harbour Biomed Shanghai Co Ltd |
Ctla-4-bindende antistoffer og anvendelser deraf
|
US11905327B2
(en)
|
2017-12-28 |
2024-02-20 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
JP7383617B2
(ja)
|
2017-12-28 |
2023-11-20 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Pd-l1に対する抗体及びそのバリアント
|
WO2019133902A2
(en)
|
2017-12-28 |
2019-07-04 |
Astute Medical, Inc. |
Antibodies and assays for ccl14
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
EP3508499A1
(en)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
|
BR112020013621A2
(pt)
|
2018-01-12 |
2020-12-01 |
Amgen Inc. |
anticorpos contra pac1 e usos dos mesmos
|
CR20200330A
(es)
|
2018-01-12 |
2020-12-23 |
Amgen Inc |
Anticuerpos anti-pd-1 y métodos de tratamiento
|
US11713353B2
(en)
|
2018-01-15 |
2023-08-01 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against PD-1
|
EP3743101A2
(en)
|
2018-01-25 |
2020-12-02 |
ACM Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ecs前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
AU2019225249A1
(en)
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
KR20200144541A
(ko)
|
2018-02-27 |
2020-12-29 |
이씨에스-프로가스트린 에스에이 |
면역치료요법용 생체표지자로서 프로가스트린
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
EP3762015A4
(en)
|
2018-03-05 |
2022-04-27 |
Janssen Biotech, Inc. |
METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
|
EP3765499A1
(en)
|
2018-03-12 |
2021-01-20 |
Zoetis Services LLC |
Anti-ngf antibodies and methods thereof
|
CN112166123B
(zh)
|
2018-03-14 |
2022-09-30 |
北京轩义医药科技有限公司 |
抗紧密连接蛋白18.2抗体
|
WO2019183266A1
(en)
|
2018-03-21 |
2019-09-26 |
ALX Oncology Inc. |
Antibodies against signal-regulatory protein alpha and methods of use
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
BR112020019026A2
(pt)
|
2018-03-24 |
2020-12-29 |
Regeneron Pharmaceuticals, Inc. |
Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
|
FI3775909T3
(fi)
|
2018-03-26 |
2023-08-01 |
Glycanostics S R O |
Välineitä ja menetelmiä proteiinin glykoprofiloimiseksi
|
AU2019242586A1
(en)
|
2018-03-26 |
2020-10-01 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
CA3093034A1
(en)
|
2018-03-30 |
2019-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
CN112004558A
(zh)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
EP3784274A1
(en)
|
2018-04-27 |
2021-03-03 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
TW202014201A
(zh)
|
2018-05-04 |
2020-04-16 |
德商馬克專利公司 |
用於治療癌症之PD-1/PD-L1,TGFβ及DNA-PK之組合抑制
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
Il−23抗体を使用してうつを治療する方法
|
US20210261647A1
(en)
|
2018-05-15 |
2021-08-26 |
Immunomic Therapeutics, Inc |
Lamp constructs comprising allergens
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
US11319373B2
(en)
|
2018-05-25 |
2022-05-03 |
Alector Llc |
Anti-SIRPA antibodies and methods of use thereof
|
MA52783A
(fr)
|
2018-06-05 |
2021-04-14 |
Amgen Inc |
Modulation de la phagocytose cellulaire dépendant de l'anticorps
|
BR112020024919A2
(pt)
|
2018-06-08 |
2021-03-09 |
Alector Llc |
Anticorpos, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, redução do risco ou tratamento de câncer e composição farmacêutica
|
MX2020013652A
(es)
|
2018-06-14 |
2022-04-21 |
Regeneron Pharma |
Animales no humanos con capacidad de reordenamiento dh-dh en las secuencias codificantes de la cadena pesada de inmunoglobulina.
|
AU2019288677A1
(en)
|
2018-06-21 |
2021-01-14 |
Yumanity Therapeutics, Inc. |
Compositions and methods for the treatment and prevention of neurological disorders
|
SG11202012446UA
(en)
|
2018-06-23 |
2021-01-28 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
WO2020014617A1
(en)
|
2018-07-13 |
2020-01-16 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
TW202011991A
(zh)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
|
EP3824287A1
(en)
|
2018-07-20 |
2021-05-26 |
Pierre Fabre Médicament |
Receptor for vista
|
MA53381A
(fr)
|
2018-07-24 |
2021-06-02 |
Amgen Inc |
Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1
|
EP3830123A1
(en)
|
2018-07-27 |
2021-06-09 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
MX2021001221A
(es)
|
2018-07-30 |
2021-06-23 |
Amgen Res Munich Gmbh |
Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
|
WO2020025792A1
(en)
|
2018-08-03 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Antibody constructs for cldn18.2 and cd3
|
EP3833389A1
(en)
|
2018-08-08 |
2021-06-16 |
Genentech, Inc. |
Use of tryptophan derivatives and l-methionine for protein formulation
|
CA3109732A1
(en)
|
2018-08-27 |
2020-03-05 |
Affimed Gmbh |
Cryopreserved nk cells preloaded with an antibody construct
|
MX2021002792A
(es)
|
2018-09-11 |
2021-05-12 |
Amgen Inc |
Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
|
US20220105176A1
(en)
|
2018-09-12 |
2022-04-07 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
CN112955747A
(zh)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
膀胱癌的治疗和诊断方法
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
KR20230148273A
(ko)
|
2018-09-24 |
2023-10-24 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
|
JP2022502399A
(ja)
|
2018-09-26 |
2022-01-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
がんの治療のためのpd−1アンタゴニスト、atrインヒビター、および白金製剤の組合せ
|
BR112021005669A2
(pt)
|
2018-09-28 |
2021-06-22 |
Amgen Inc. |
anticorpos contra bcma solúvel
|
CN112969503A
(zh)
|
2018-10-03 |
2021-06-15 |
斯塔滕生物技术有限公司 |
对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
CN113164447A
(zh)
|
2018-10-15 |
2021-07-23 |
默克专利股份公司 |
利用dna烷化剂和atr抑制剂的组合疗法
|
MX2021004348A
(es)
|
2018-10-18 |
2021-05-28 |
Genentech Inc |
Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
|
AU2019363713A1
(en)
|
2018-10-24 |
2021-05-27 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Vaccination and antibody generation platform
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
EP3873525A4
(en)
|
2018-11-02 |
2022-07-13 |
Annexon, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURIES
|
AU2019375413A1
(en)
|
2018-11-05 |
2021-05-27 |
Genentech, Inc. |
Methods of producing two chain proteins in prokaryotic host cells
|
US20220011301A1
(en)
|
2018-11-16 |
2022-01-13 |
Roche Diagnostics Operations, Inc. |
Streptavidin-coated solid phases with a member of a binding pair
|
CN113395979A
(zh)
|
2018-11-20 |
2021-09-14 |
詹森生物科技公司 |
用抗il-23特异性抗体治疗银屑病的安全且有效的方法
|
US20220098310A1
(en)
|
2018-12-06 |
2022-03-31 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
JP2022518399A
(ja)
|
2019-01-14 |
2022-03-15 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニスト及びrnaワクチンを用いてがんを処置する方法
|
KR20210116540A
(ko)
|
2019-01-15 |
2021-09-27 |
얀센 바이오테크 인코포레이티드 |
소아 특발성 관절염의 치료를 위한 항-tnf 항체 조성물 및 방법
|
CN113330031A
(zh)
|
2019-01-23 |
2021-08-31 |
詹森生物科技公司 |
用于在治疗银屑病关节炎的方法中使用的抗tnf抗体组合物
|
EP3914615A1
(en)
|
2019-01-23 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Methods of producing multimeric proteins in eukaryotic host cells
|
EP3917968A1
(en)
|
2019-01-30 |
2021-12-08 |
Nomocan Pharmaceuticals LLC |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
JP2022519649A
(ja)
|
2019-02-08 |
2022-03-24 |
ジェネンテック, インコーポレイテッド |
がんの診断および治療方法
|
CN112703013B
(zh)
|
2019-02-22 |
2022-09-30 |
武汉友芝友生物制药股份有限公司 |
Cd3抗原结合片段及其应用
|
US11242407B2
(en)
|
2019-02-26 |
2022-02-08 |
Inspirna, Inc. |
High-affinity anti-MERTK antibodies and uses thereof
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
US20220153830A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
JP7379654B2
(ja)
|
2019-03-15 |
2023-11-14 |
カーティザン セラピューティクス,インコーポレーテッド |
抗bcmaキメラ抗原受容体
|
US20200331996A1
(en)
|
2019-03-18 |
2020-10-22 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
|
CN113661180A
(zh)
|
2019-03-27 |
2021-11-16 |
宾夕法尼亚大学董事会 |
Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
|
JP2022524215A
(ja)
|
2019-03-28 |
2022-04-28 |
ダニスコ・ユーエス・インク |
改変抗体
|
BR112021021165A2
(pt)
|
2019-04-24 |
2022-01-04 |
Heidelberg Pharma Res Gmbh |
Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
EP3972690A4
(en)
|
2019-05-23 |
2023-07-05 |
Janssen Biotech, Inc. |
METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
|
US20200369759A1
(en)
|
2019-05-23 |
2020-11-26 |
Fibrogen, Inc. |
Methods of treatment of muscular dystrophies
|
AU2020283890A1
(en)
|
2019-05-30 |
2021-12-16 |
Amgen Inc. |
Engineering the hinge region to drive antibody dimerization
|
AU2020288404A1
(en)
|
2019-06-03 |
2022-02-03 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
EP3976648A1
(en)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
MA56120A
(fr)
|
2019-06-07 |
2022-04-13 |
Amgen Inc |
Constructions de liaison bispécifiques
|
AU2020290573A1
(en)
|
2019-06-13 |
2021-11-04 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
EP3990493A1
(en)
|
2019-06-28 |
2022-05-04 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
EP3993623A1
(en)
|
2019-07-01 |
2022-05-11 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
BR112021026410A2
(pt)
|
2019-07-01 |
2022-02-08 |
Tonix Pharma Ltd |
Anticorpos anti-cd154 e usos dos mesmos
|
CA3144956A1
(en)
|
2019-07-01 |
2021-01-07 |
Trianni, Inc. |
Transgenic mammals and methods of use
|
CN114401992A
(zh)
|
2019-07-05 |
2022-04-26 |
艾欧麦克斯治疗股份公司 |
结合igsf11(vsig3)的igc2的抗体及其用途
|
EP3763737A1
(en)
|
2019-07-12 |
2021-01-13 |
Eberhard Karls Universität Tübingen |
Binding compounds of penicillin binding protein 2 a
|
MX2022000988A
(es)
|
2019-07-26 |
2022-05-03 |
Amgen Inc |
Proteinas de union a antigeno anti-il13.
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
EP3785536B1
(en)
|
2019-08-28 |
2022-01-26 |
Trianni, Inc. |
Adam6 knockin mice
|
CR20220076A
(es)
|
2019-08-30 |
2022-06-24 |
Agenus Inc |
Anticuerpos anti-cd96 y sus métodos de uso
|
WO2021043206A1
(zh)
|
2019-09-03 |
2021-03-11 |
百奥泰生物制药股份有限公司 |
一种抗tigit免疫抑制剂及应用
|
WO2021046159A1
(en)
|
2019-09-04 |
2021-03-11 |
Genentech, Inc. |
Cd8 binding agents and uses thereof
|
MX2022002981A
(es)
|
2019-09-10 |
2022-04-06 |
Amgen Inc |
Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
|
JP2022547577A
(ja)
|
2019-09-12 |
2022-11-14 |
ジェネンテック, インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
JP2022552282A
(ja)
|
2019-10-09 |
2022-12-15 |
エスティーキューブ アンド カンパニー |
グリコシル化lag3に対して特異的な抗体およびその使用方法
|
EP4045528A1
(en)
|
2019-10-18 |
2022-08-24 |
Immunomic Therapeutics, Inc. |
Improved lamp constructs comprising cancer antigens
|
WO2021076930A1
(en)
|
2019-10-18 |
2021-04-22 |
The Regents Of The University Of California |
Plxdc activators and their use in the treatment of blood vessel disorders
|
EP4051298A1
(en)
|
2019-11-01 |
2022-09-07 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progentor cells
|
JP2023501971A
(ja)
|
2019-11-01 |
2023-01-20 |
アレス トレーディング ソシエテ アノニム |
癌の治療のための、放射線療法と共に用いるPD-1、TGFβ、及びATMの組み合わせ阻害
|
EP4054633A1
(en)
|
2019-11-05 |
2022-09-14 |
Merck Patent GmbH |
Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
|
US20220389103A1
(en)
|
2019-11-06 |
2022-12-08 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
JP2022553813A
(ja)
|
2019-11-08 |
2022-12-26 |
アムジエン・インコーポレーテツド |
ヘテロIgG分子の対合のための電荷対変異の操作
|
WO2021097344A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
EP3822288A1
(en)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
|
EP3825330A1
(en)
|
2019-11-19 |
2021-05-26 |
International-Drug-Development-Biotech |
Anti-cd117 antibodies and methods of use thereof
|
WO2021102049A1
(en)
|
2019-11-19 |
2021-05-27 |
Amgen Inc. |
Novel multispecific antibody format
|
JP2023504172A
(ja)
|
2019-12-02 |
2023-02-01 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ペプチド-mhc iiタンパク質構築物およびそれらの使用
|
CA3158565A1
(en)
|
2019-12-05 |
2021-06-10 |
Tina SCHWABE |
Methods of use of anti-trem2 antibodies
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
WO2021118930A2
(en)
|
2019-12-09 |
2021-06-17 |
Genentech, Inc. |
Anti-pd-l1 antibody formulations
|
EP4073119A1
(en)
|
2019-12-12 |
2022-10-19 |
Alector LLC |
Methods of use of anti-cd33 antibodies
|
CA3164129A1
(en)
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
EP4081554A1
(en)
|
2019-12-27 |
2022-11-02 |
Affimed GmbH |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
AU2021205893A1
(en)
|
2020-01-08 |
2022-06-23 |
Synthis Therapeutics, Inc. |
ALK5 inhibitor conjugates and uses thereof
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
JP2023512654A
(ja)
|
2020-01-31 |
2023-03-28 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
US20230159637A1
(en)
|
2020-02-24 |
2023-05-25 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
CA3174103A1
(en)
|
2020-03-06 |
2021-09-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
CN115485295A
(zh)
|
2020-03-10 |
2022-12-16 |
麻省理工学院 |
NPM1c阳性癌症的免疫疗法的组合物和方法
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
EP4121459A1
(en)
|
2020-03-19 |
2023-01-25 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
WO2021197340A1
(zh)
|
2020-03-31 |
2021-10-07 |
百奥泰生物制药股份有限公司 |
用于治疗冠状病毒的抗体、融合蛋白及其应用
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2021203030A2
(en)
|
2020-04-03 |
2021-10-07 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
WO2021222181A2
(en)
|
2020-04-27 |
2021-11-04 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
MX2022013493A
(es)
|
2020-04-27 |
2023-02-22 |
Magenta Therapeutics Inc |
Metodos y composiciones para transducir celulas madre y progenitoras hematopoyeticas in vivo.
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
JP2023527293A
(ja)
|
2020-05-19 |
2023-06-28 |
アムジエン・インコーポレーテツド |
Mageb2結合構築物
|
EP3915641A1
(en)
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
WO2021243320A2
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
|
CN115803062A
(zh)
|
2020-06-03 |
2023-03-14 |
博泰康医药公司 |
滋养层细胞表面抗原2(trop-2)抗体
|
WO2021247812A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
CA3181672A1
(en)
|
2020-06-18 |
2021-12-23 |
Shi Li |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
WO2021263167A2
(en)
|
2020-06-26 |
2021-12-30 |
Amgen Inc. |
Il-10 muteins and fusion proteins thereof
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
US20240010720A1
(en)
|
2020-07-06 |
2024-01-11 |
Iomx Therapeutics Ag |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
US20230256114A1
(en)
|
2020-07-07 |
2023-08-17 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Tigit及cd112r阻斷
|
WO2022020636A2
(en)
|
2020-07-24 |
2022-01-27 |
Amgen Inc. |
Immunogens derived from sars-cov2 spike protein
|
WO2022026699A1
(en)
|
2020-07-31 |
2022-02-03 |
Genentech, Inc. |
Anti-integrin beta7 antibody formulations and devices
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック, インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
KR20230042301A
(ko)
|
2020-08-04 |
2023-03-28 |
애벗트 라보라토리이즈 |
샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
|
US20230287126A1
(en)
|
2020-08-07 |
2023-09-14 |
Bio-Thera Solutions, Ltd. |
Anti-pd-l1 antibody and use thereof
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
EP4200338A1
(en)
|
2020-08-20 |
2023-06-28 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
WO2022047381A1
(en)
|
2020-08-31 |
2022-03-03 |
Genentech, Inc. |
Methods for producing antibodies
|
EP4208197A1
(en)
|
2020-09-04 |
2023-07-12 |
Rutgers, The State University of New Jersey |
Sars-cov-2 vaccines and antibodies
|
IL301137A
(en)
|
2020-09-11 |
2023-05-01 |
Regeneron Pharma |
Identification and production of antigen-specific antibodies
|
WO2022056490A1
(en)
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Chimeric antigen receptors for treatment of cancer
|
EP4225786A2
(en)
|
2020-10-07 |
2023-08-16 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
US20230365709A1
(en)
|
2020-10-08 |
2023-11-16 |
Affimed Gmbh |
Trispecific binders
|
EP4229081A1
(en)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
AU2021370991A1
(en)
|
2020-11-02 |
2023-06-22 |
Ares Trading S.A. |
Combination treatment of cancer
|
US20240050563A1
(en)
|
2020-11-02 |
2024-02-15 |
Ares Trading S.A. |
Combination Treatment of Cancer
|
CN116829951A
(zh)
|
2020-11-02 |
2023-09-29 |
豪夫迈·罗氏有限公司 |
SARS-CoV-2核衣壳抗体
|
EP3992205A1
(en)
|
2020-11-03 |
2022-05-04 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Sars coronavirus-2 spike protein binding compounds
|
EP4240762A1
(en)
|
2020-11-03 |
2023-09-13 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
|
IL301926A
(en)
|
2020-11-06 |
2023-06-01 |
Amgen Inc |
Antigen binding domain with reduced cleavage rate
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
EP4242232A1
(en)
|
2020-11-06 |
2023-09-13 |
Bio-Thera Solutions, Ltd. |
Bispecific antibody and use thereof
|
AR124019A1
(es)
|
2020-11-06 |
2023-02-01 |
Amgen Res Munich Gmbh |
Construcciones polipeptídicas que se unen a cd3
|
EP4240768A2
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
JP2023548595A
(ja)
|
2020-11-10 |
2023-11-17 |
アムジエン・インコーポレーテツド |
多重特異性抗原結合ドメインの新規のリンカー
|
EP4253415A1
(en)
|
2020-11-12 |
2023-10-04 |
Mabwell (Shanghai) Bioscience Co., Ltd. |
Antibody and preparation method therefor
|
WO2022106205A1
(en)
|
2020-11-18 |
2022-05-27 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Corona virus spike protein binding compounds
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022120033A1
(en)
|
2020-12-03 |
2022-06-09 |
Amgen Inc. |
Immunoglobuline constructs with multiple binding domains
|
IL303529A
(en)
|
2020-12-09 |
2023-08-01 |
Trianni Inc |
Heavy chain antibodies only
|
JP2024500399A
(ja)
|
2020-12-16 |
2024-01-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化Fcアルファ受容体を発現するマウス
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
IL303868A
(en)
|
2020-12-23 |
2023-08-01 |
Regeneron Pharma |
Nucleic acids encoding anchor-modified antibodies and uses thereof
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
CN116963750A
(zh)
|
2021-01-06 |
2023-10-27 |
通尼克斯制药有限公司 |
用经修饰的抗-cd154抗体诱导免疫耐受的方法
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
JP2024504493A
(ja)
|
2021-01-28 |
2024-01-31 |
ヴァクスィーンヴェント ゲーエムベーハー |
B細胞媒介性免疫応答を調節するための方法及び手段
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
EP4301782A1
(en)
|
2021-03-05 |
2024-01-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
KR20230148226A
(ko)
|
2021-03-10 |
2023-10-24 |
이뮤노웨이크 인크. |
면역조절 분자 및 이의 용도
|
WO2022190034A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
IL305802A
(en)
|
2021-03-12 |
2023-11-01 |
Janssen Biotech Inc |
A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
|
TW202300521A
(zh)
|
2021-03-15 |
2023-01-01 |
美商建南德克公司 |
治療狼瘡性腎炎的組成物及方法
|
WO2022197776A1
(en)
|
2021-03-16 |
2022-09-22 |
Magenta Therapeutics, Inc. |
Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
|
EP4314078A1
(en)
|
2021-04-02 |
2024-02-07 |
Amgen Inc. |
Mageb2 binding constructs
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
KR20230167097A
(ko)
|
2021-04-09 |
2023-12-07 |
제넨테크, 인크. |
Raf 억제제와 pd-1 축 억제제를 사용한 병용 요법
|
CN117651714A
(zh)
|
2021-04-20 |
2024-03-05 |
美国安进公司 |
多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
|
WO2022232376A1
(en)
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
EP4333900A2
(en)
|
2021-05-03 |
2024-03-13 |
Merck Patent GmbH |
Her2 targeting fc antigen binding fragment-drug conjugates
|
WO2022235628A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
WO2022235759A1
(en)
|
2021-05-05 |
2022-11-10 |
Trianni, Inc. |
Transgenic rodents expressing chimeric equine-rodent antibodies and methods of use thereof
|
WO2022235940A1
(en)
|
2021-05-06 |
2022-11-10 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
CN117279947A
(zh)
|
2021-05-06 |
2023-12-22 |
安进研发(慕尼黑)股份有限公司 |
用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
AU2022280341A1
(en)
|
2021-05-25 |
2024-01-04 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
AU2022288571A1
(en)
|
2021-06-07 |
2024-01-04 |
Ares Trading S.A. |
Combination treatment of cancer
|
AU2022293999A1
(en)
|
2021-06-14 |
2023-11-30 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
BR112023026199A2
(pt)
|
2021-06-14 |
2024-03-05 |
Abbott Lab |
Métodos para diagnosticar ou auxiliar no diagnóstico de lesão cerebral causada por energia acústica, energia eletromagnética, onda de sobrepressurização e/ou rajada de vento
|
CA3224001A1
(en)
|
2021-06-25 |
2022-12-29 |
Amgen Inc. |
Treatment of cardiovascular disease with trem-1 antigen binding proteins
|
WO2023281463A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
IL309987A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-IL12/IL23 antibody compositions
|
AU2022306144A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
WO2023010118A1
(en)
|
2021-07-29 |
2023-02-02 |
Vor Biopharma Inc. |
Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
|
AU2022320948A1
(en)
|
2021-07-30 |
2024-01-18 |
Affimed Gmbh |
Duplexbodies
|
AU2022324456A1
(en)
|
2021-08-05 |
2024-02-15 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
AU2022328390A1
(en)
|
2021-08-10 |
2024-03-21 |
Adimab, Llc |
Anti-gdf15 antibodies, compositions and uses thereof
|
AU2022330106A1
(en)
|
2021-08-16 |
2024-03-21 |
Hemogenyx Pharmaceuticals Llc |
Anti-flt3 antibodies, cars, car t cells and methods of use
|
IL310861A
(en)
|
2021-08-17 |
2024-04-01 |
Hemogenyx Pharmaceuticals Llc |
Bispecific antibodies against FLT3 and CD3 and methods of use
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022339667A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
WO2023034571A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
CA3232212A1
(en)
|
2021-10-01 |
2023-04-06 |
Ping XIANG |
Transgenic rodents for cell line identification and enrichment
|
CA3235627A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
WO2023072904A1
(en)
|
2021-10-26 |
2023-05-04 |
F. Hoffmann-La Roche Ag |
Monoclonal antibodies specific for sars-cov-2 rbd
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
AR127568A1
(es)
|
2021-11-03 |
2024-02-07 |
Affimed Gmbh |
Ligandos biespecíficos de cd16a
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
CA3235395A1
(en)
|
2021-11-10 |
2023-05-19 |
Peter Burrows |
Transgenic mammals and methods of use thereof
|
WO2023084488A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023097024A1
(en)
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023111168A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
A novel antibody for detection of amyloid beta 42 (aβ42)
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023137161A1
(en)
|
2022-01-14 |
2023-07-20 |
Amgen Inc. |
Triple blockade of tigit, cd112r, and pd-l1
|
WO2023139292A1
(en)
|
2022-01-24 |
2023-07-27 |
Cambridge Enterprise Limited |
Tau therapy
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
EP4245772A1
(en)
|
2022-03-18 |
2023-09-20 |
Netris Pharma |
Anti-netrin-1 antibody to treat liver inflammation
|
EP4249509A1
(en)
|
2022-03-22 |
2023-09-27 |
Netris Pharma |
Anti-netrin-1 antibody against arthritis-associated pain
|
WO2023186968A1
(en)
|
2022-03-29 |
2023-10-05 |
Netris Pharma |
Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
WO2023194539A1
(en)
|
2022-04-07 |
2023-10-12 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index of amatoxin-antibody conjugates
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
WO2023235415A1
(en)
|
2022-06-01 |
2023-12-07 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024038165A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Ltd |
T cell receptor fusion proteins specific for mage a4
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|